[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Horiba Instruments, Inc dba Horiba Medical\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":265},{"warningLetters":4,"total":264},[5,31,50,73,92,110,129,153,174,191,209,226,245],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},2119,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-04-25T13:20:00Z\">04\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-02-13T05:00:00Z\">02\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedivance-instruments-ltd-647562-02132023\">Medivance Instruments Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)\u003Cbr \u002F>\r\n","","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sidney Grant\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medivance Instruments Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Barretts Green Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Harlesden\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>London\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>NW10 7AE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Grant:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Harlesden, London, United Kingdom on August 8, 2022, through August 11, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Velopex Aquacut Fluid Abrasion Unit (“Velopex Device”) and various accessories as part of the Velopex AquaCare Dental Abrasion line of products. These products are intended for use in a range of dental procedures, including sealant preparation, composite removal and restoration, and cavity preparation. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you dated September 1, 2022, concerning our investigator’s observations noted on the Form FDA 483 (“FDA 483”), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Your firm currently holds a 510(k) clearance (K024105) for the Velopex Device, which was issued on October 9, 2003. However, since the time it was cleared, the Velopex Device has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, your firm has made significant changes that include, among other things, the incorporation of a new air regulator and changes to the materials used in the powder tubing\u002Fvalves. Firm documents inspected by FDA noted that the incorporation of a new air regulator is intended to address the risk or reliability and pipe stress failure of the device by changing the parameters of the air flow and operating pressure range that are factory set. The changes to the air regulator may impact the ratio of the air\u002Fwater\u002Fpowder mixture that contacts the surface of the dentition and the efficiency of how that mixture moves through the system. Further, the changed powder tubing\u002Fvalve materials included a container molded insert and slide insider, which may impact the performance of the drip of the powder.\u003C\u002Fp>\n\n\u003Cp>The changes outlined in this warning letter and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified Velopex devices (“Modified Velopex Devices”). (See 21 CFR 807.81(a)(3).)\u003C\u002Fp>\n\n\u003Cp>You did not submit any new 510(k) in association with the Modified Velopex Devices. The Modified Velopex Devices are therefore misbranded under section 502(o) the Act, 21 U.S.C. §352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified Velopex Devices, as required by section 510(k) of the Act.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the Modified Velopex Devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review and approval of design changes before their implementation as required by 21 CFR 820.30(i). For example, your firm has not verified or validated design changes during and after your firm’s design and development process prior to implementation. Your firm also stated to FDA that certain design changes for your AquaCare devices, including the Aquacut and AquaCare Single and Twin devices, were validated but not adequately documented.\u003C\u002Fp>\n\n\u003Cp>The response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Design and Development procedure to meet the requirements of 21 CFR 820.30(i). Also, your firm states it plans to conduct effectiveness checks of these revised procedures. Your firm additionally provided red-lined portions of the current Design and Development procedure to describe the specific changes that were made to the procedure. However, your firm’s response failed to provide a plan on how it would retrospectively validate and, where appropriate, verify that the changes to its 510(k) cleared device were safe and effective for the device’s current intended use. Your response also failed to explain how your firm was going to establish and maintain procedures for the identification, documentation, validation (or, where appropriate, verification), review, and approval of design changes before their implementation on devices currently distributed in the US marketplace.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Your firm failed to conduct CAPA investigations and failed to verify the effectiveness of Corrective Actions taken as part of a CAPA, or indicate that verification was not required, as required by your firm’s corrective and preventive action (CAPA) procedure. For example, your firm’s corrective and preventive action (CAPA) procedure does not have a requirement to verify or validate corrective and\u002For preventive action for every CAPA activity. Upon review of thirty CAPA records from 2019to 2021 (including CAPAs 2019-1 to 2019-5, 2019-7 to 2019-16, 2020-1, 2020-2, and 2021-1 to 2021-13), it was observed that none of these records were evaluated for effectiveness. Further, some CAPA activity lacked corrective and\u002For preventive actions. Accordingly, your firm failed to verify or validate the effectiveness of CAPA actions to ensure the finished device was not adversely affected.\u003C\u002Fp>\n\n\u003Cp>The response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its CAPA procedure, CAPA Request form and CAPA Log (and provided copies of these revised documents as part of your response) to meet the requirements of 21 CFR 820.100(a). Your firm also noted that staff would be trained on how to implement the updated CAPA procedure, form, and log. However, the firm’s plan did not describe how it planned to address currently outstanding CAPAs, nor provide a timeline on when it anticipated these outstanding CAPAs to be resolved.\u003C\u002Fp>\n\n\u003Cp>3. Failure to review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate, as required by 21 CFR 820.198(b). For example, your Customer Complaints procedure states all customer complaints must be investigated and if rejected, a justification must be documented. During inspection, your firm stated to FDA that complaint investigations are carried out but might not have been documented. However, forty-eight customer complaints from 2019-2022 were reviewed where no investigation was performed, and a justification was not documented as to why no investigation was performed.\u003C\u002Fp>\n\n\u003Cp>The response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Customer Complaints procedure to meet the requirements of 21 CFR 820.198(b). Also, your firm has plans to revise the Customer Complaints Form; generate a new Faults Investigation form and retrain all required personnel. Your firm provided copies of the revised procedure, revised Customer Complaints form and a new Faults Investigation form as part of your investigation. Your firm has yet to complete personnel training. Although your firm’s plan indicates a commitment to resolve new complaints that you receive, it does not address a commitment and timeline to investigate and resolve current, pending complaints such as the ones identified as part of FDA’s investigation. Investigation and resolution of complaints is required per your firm’s revised SOP; which states in part that complaints shall be evaluated to determine whether a CAPA will be required, shall be conducted; and if required the QA\u002FRA department will be notified to coordinate initiation and resolution of the CAPA.\u003C\u002Fp>\n\n\u003Cp>4. Failure to maintain device history records (DHR's). Each manufacturer shall establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record(DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm does not have procedures to ensure the DHR for each unit of your device is manufactured in accordance with the DMR and requirements of the regulation. Your firm does not have a DHR procedure. In addition, your firm’s device DHRs for your AquaCare device lacks identification labeling as well as a Unique Device Identifier (UDI) or Universal Product Code (UPC) for each device unit.\u003C\u002Fp>\n\n\u003Cp>The adequacy of the response dated 09\u002F01\u002F2022 cannot be determined at this time. Your firm identified its plan to revise its AquaCare Final test Certificate and generate a new Device History Records procedure to meet the requirements of 21 CFR 820.184. The plan may be appropriate based on the documentation provided in the response, but your firm has not completed implementation of the plan, nor documented the plan’s effectiveness. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Velopex AquaCare Dental Abrasion System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following: failure to submit an MDR report no later than 30 calendar days after the day you receive or otherwise become aware of information that reasonably suggests a marketed device either may have caused or contributed to a death or serious injury, or has malfunctioned and would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur as required by 21 CFR 803.50(a). For example, the information included for your firm’s incident report \u003Cstrong>(b)(4)\u003C\u002Fstrong> reasonably suggests that a patient sustained an injury (i.e., surgical emphysema and an observed area of traumatic ulceration) from your firm’s AquaCare device and subsequently underwent antibiotic treatment. There is no information included in the complaint that rules out that the device may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of a serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the referenced event on April 12, 2019. However, your firm didn’t submit an MDR for the referenced event.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated September 1, 2022, is not adequate. Your response noted that your firm developed an MDR procedure and is in process of establishing an eMDR account for the submission of the referenced report. Based on FDA’s records, your firm had a certificate with Electronic Submissions Gateway (ESG) on August 22, 2022. However, your firm did not complete its load test and guidance compliance submission for eMDR. Your firm should follow the instructions located at How to Enroll in eMDR Program | FDA under step 2 of “Low Volume Enrollment Process” to complete the testing in order to obtain its Web Trader production account. Further, our review concluded that the newly developed MDR procedure is deficient as indicated above and your firm does not plan to take the systemic corrective actions including a retrospective review of complaints for reportability.\u003C\u002Fp>\n\n\u003Cp>Your firm also failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the documents titled “Vigilance System”, Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 03\u002F10\u002F2021 and “Vigilance System – Incident Reporting Procedures”, Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 07\u002F11\u002F2021 as its MDR procedure. However, the procedure does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements of 21 CFR 803.17. Your firm’s response dated September 1, 2022, is not adequate. Your response provided a copy of a newly created MDR procedure titled “Vigilance System – Incident Reporting Procedure in the USA”, Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 8\u002F1\u002F2022. After reviewing the procedure outlined in your response, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>a. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits definitions of the terms “malfunction”, “caused or contributed” and “serious injury”. The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>b. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including information that was evaluated to determine if an event was reportable. Additionally, the procedure, as written, designates the initial importer Velopex International as the authorized reporter to fulfil the manufacturer’s reporting obligation. Under the MDR regulation, both manufacturers and importers are required to make reports as described in 21 CFR Part803.The section 19(b) of your firm’s procedure states that Velopex International will be required to act as the Manufacturer and will need to report to the FDA directly as required by 21 CFR 803.50 and 803.52. However, this statement does not exempt any mandatory reporting entity from fulfilling its individual reporting requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #647562 when replying. If you have any questions about the contents of this letter, please contact: Michael Adjodha at (301) 796-6276.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia, Respiratory,\u003Cbr>\nENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered Agent Solutions Inc.\u003Cbr>\n1701 Directors Boulevard, Suite 300\u003Cbr>\nAustin, TX 78744\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Sidney Grant\n\nRecipient Title\n\nManaging Director, CEO\n\nMedivance Instruments Ltd.\n\nBarretts Green Road\n\nHarlesden\n\nLondon\n\nNW10 7AE\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nFebruary 13, 2023\n\nDear Mr. Grant:\n\nDuring an inspection of your firm located in Harlesden, London, United Kingdom on August 8, 2022, through August 11, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Velopex Aquacut Fluid Abrasion Unit (“Velopex Device”) and various accessories as part of the Velopex AquaCare Dental Abrasion line of products. These products are intended for use in a range of dental procedures, including sealant preparation, composite removal and restoration, and cavity preparation. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received a response from you dated September 1, 2022, concerning our investigator’s observations noted on the Form FDA 483 (“FDA 483”), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\nYour firm currently holds a 510(k) clearance (K024105) for the Velopex Device, which was issued on October 9, 2003. However, since the time it was cleared, the Velopex Device has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, your firm has made significant changes that include, among other things, the incorporation of a new air regulator and changes to the materials used in the powder tubing\u002Fvalves. Firm documents inspected by FDA noted that the incorporation of a new air regulator is intended to address the risk or reliability and pipe stress failure of the device by changing the parameters of the air flow and operating pressure range that are factory set. The changes to the air regulator may impact the ratio of the air\u002Fwater\u002Fpowder mixture that contacts the surface of the dentition and the efficiency of how that mixture moves through the system. Further, the changed powder tubing\u002Fvalve materials included a container molded insert and slide insider, which may impact the performance of the drip of the powder.\n\nThe changes outlined in this warning letter and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified Velopex devices (“Modified Velopex Devices”). (See 21 CFR 807.81(a)(3).)\n\nYou did not submit any new 510(k) in association with the Modified Velopex Devices. The Modified Velopex Devices are therefore misbranded under section 502(o) the Act, 21 U.S.C. §352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified Velopex Devices, as required by section 510(k) of the Act.\n\nOur inspection revealed that the Modified Velopex Devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These deficiencies include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review and approval of design changes before their implementation as required by 21 CFR 820.30(i). For example, your firm has not verified or validated design changes during and after your firm’s design and development process prior to implementation. Your firm also stated to FDA that certain design changes for your AquaCare devices, including the Aquacut and AquaCare Single and Twin devices, were validated but not adequately documented.\n\nThe response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Design and Development procedure to meet the requirements of 21 CFR 820.30(i). Also, your firm states it plans to conduct effectiveness checks of these revised procedures. Your firm additionally provided red-lined portions of the current Design and Development procedure to describe the specific changes that were made to the procedure. However, your firm’s response failed to provide a plan on how it would retrospectively validate and, where appropriate, verify that the changes to its 510(k) cleared device were safe and effective for the device’s current intended use. Your response also failed to explain how your firm was going to establish and maintain procedures for the identification, documentation, validation (or, where appropriate, verification), review, and approval of design changes before their implementation on devices currently distributed in the US marketplace.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Your firm failed to conduct CAPA investigations and failed to verify the effectiveness of Corrective Actions taken as part of a CAPA, or indicate that verification was not required, as required by your firm’s corrective and preventive action (CAPA) procedure. For example, your firm’s corrective and preventive action (CAPA) procedure does not have a requirement to verify or validate corrective and\u002For preventive action for every CAPA activity. Upon review of thirty CAPA records from 2019to 2021 (including CAPAs 2019-1 to 2019-5, 2019-7 to 2019-16, 2020-1, 2020-2, and 2021-1 to 2021-13), it was observed that none of these records were evaluated for effectiveness. Further, some CAPA activity lacked corrective and\u002For preventive actions. Accordingly, your firm failed to verify or validate the effectiveness of CAPA actions to ensure the finished device was not adversely affected.\n\nThe response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its CAPA procedure, CAPA Request form and CAPA Log (and provided copies of these revised documents as part of your response) to meet the requirements of 21 CFR 820.100(a). Your firm also noted that staff would be trained on how to implement the updated CAPA procedure, form, and log. However, the firm’s plan did not describe how it planned to address currently outstanding CAPAs, nor provide a timeline on when it anticipated these outstanding CAPAs to be resolved.\n\n3. Failure to review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate, as required by 21 CFR 820.198(b). For example, your Customer Complaints procedure states all customer complaints must be investigated and if rejected, a justification must be documented. During inspection, your firm stated to FDA that complaint investigations are carried out but might not have been documented. However, forty-eight customer complaints from 2019-2022 were reviewed where no investigation was performed, and a justification was not documented as to why no investigation was performed.\n\nThe response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Customer Complaints procedure to meet the requirements of 21 CFR 820.198(b). Also, your firm has plans to revise the Customer Complaints Form; generate a new Faults Investigation form and retrain all required personnel. Your firm provided copies of the revised procedure, revised Customer Complaints form and a new Faults Investigation form as part of your investigation. Your firm has yet to complete personnel training. Although your firm’s plan indicates a commitment to resolve new complaints that you receive, it does not address a commitment and timeline to investigate and resolve current, pending complaints such as the ones identified as part of FDA’s investigation. Investigation and resolution of complaints is required per your firm’s revised SOP; which states in part that complaints shall be evaluated to determine whether a CAPA will be required, shall be conducted; and if required the QA\u002FRA department will be notified to coordinate initiation and resolution of the CAPA.\n\n4. Failure to maintain device history records (DHR's). Each manufacturer shall establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record(DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm does not have procedures to ensure the DHR for each unit of your device is manufactured in accordance with the DMR and requirements of the regulation. Your firm does not have a DHR procedure. In addition, your firm’s device DHRs for your AquaCare device lacks identification labeling as well as a Unique Device Identifier (UDI) or Universal Product Code (UPC) for each device unit.\n\nThe adequacy of the response dated 09\u002F01\u002F2022 cannot be determined at this time. Your firm identified its plan to revise its AquaCare Final test Certificate and generate a new Device History Records procedure to meet the requirements of 21 CFR 820.184. The plan may be appropriate based on the documentation provided in the response, but your firm has not completed implementation of the plan, nor documented the plan’s effectiveness. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy.\n\nOur inspection also revealed that your firm’s Velopex AquaCare Dental Abrasion System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following: failure to submit an MDR report no later than 30 calendar days after the day you receive or otherwise become aware of information that reasonably suggests a marketed device either may have caused or contributed to a death or serious injury, or has malfunctioned and would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur as required by 21 CFR 803.50(a). For example, the information included for your firm’s incident report (b)(4) reasonably suggests that a patient sustained an injury (i.e., surgical emphysema and an observed area of traumatic ulceration) from your firm’s AquaCare device and subsequently underwent antibiotic treatment. There is no information included in the complaint that rules out that the device may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of a serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the referenced event on April 12, 2019. However, your firm didn’t submit an MDR for the referenced event.\n\nYour firm’s response dated September 1, 2022, is not adequate. Your response noted that your firm developed an MDR procedure and is in process of establishing an eMDR account for the submission of the referenced report. Based on FDA’s records, your firm had a certificate with Electronic Submissions Gateway (ESG) on August 22, 2022. However, your firm did not complete its load test and guidance compliance submission for eMDR. Your firm should follow the instructions located at How to Enroll in eMDR Program | FDA under step 2 of “Low Volume Enrollment Process” to complete the testing in order to obtain its Web Trader production account. Further, our review concluded that the newly developed MDR procedure is deficient as indicated above and your firm does not plan to take the systemic corrective actions including a retrospective review of complaints for reportability.\n\nYour firm also failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the documents titled “Vigilance System”, Document (b)(4), dated 03\u002F10\u002F2021 and “Vigilance System – Incident Reporting Procedures”, Document (b)(4), dated 07\u002F11\u002F2021 as its MDR procedure. However, the procedure does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements of 21 CFR 803.17. Your firm’s response dated September 1, 2022, is not adequate. Your response provided a copy of a newly created MDR procedure titled “Vigilance System – Incident Reporting Procedure in the USA”, Document (b)(4), dated 8\u002F1\u002F2022. After reviewing the procedure outlined in your response, the following deficiencies were noted:\n\na. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits definitions of the terms “malfunction”, “caused or contributed” and “serious injury”. The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including information that was evaluated to determine if an event was reportable. Additionally, the procedure, as written, designates the initial importer Velopex International as the authorized reporter to fulfil the manufacturer’s reporting obligation. Under the MDR regulation, both manufacturers and importers are required to make reports as described in 21 CFR Part803.The section 19(b) of your firm’s procedure states that Velopex International will be required to act as the Manufacturer and will need to report to the FDA directly as required by 21 CFR 803.50 and 803.52. However, this statement does not exempt any mandatory reporting entity from fulfilling its individual reporting requirements.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #647562 when replying. If you have any questions about the contents of this letter, please contact: Michael Adjodha at (301) 796-6276.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia, Respiratory,\n\nENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nRegistered Agent Solutions Inc.\n\n1701 Directors Boulevard, Suite 300\n\nAustin, TX 78744","Medivance Instruments Ltd.","medivance-instruments-ltd-647562-02132023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedivance-instruments-ltd-647562-02132023","2026-10-26T08:09:23.334631+00:00","Warning Letter","Issued","2023-04-25","647562","Medical Devices","Mr. Sidney Grant","2026-08-20T01:08:27.03+00:00","2023-02-13",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":20,"letter_url":43,"updated_at":44,"action_type":23,"case_status":24,"posted_date":45,"marcs_cms_no":46,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":49,"medical_device_id":20,"response_letter_date":20},3399,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2021-04-15T17:00:00Z\">04\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-25T04:00:00Z\">03\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fikcon-investments-inc-dba-ikcon-medical-609791-03252021\">Ikcon Investments, Inc dba Ikcon Medical\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ricardo Emmanuel Weichsel Upton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ikcon Investments, Inc dba Ikcon Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14653 Caminito Lazanja\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92127\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@ikconmedical.com\"> info@ikconmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 25, 2021\u003C\u002Fp>\n\n\u003Cp>TO:&nbsp;\u003C\u002Fp>\n\n\u003Cp>6540 Lusk Blvd Suite C-111\u003Cbr>\nSan Diego, CA 92121\u003C\u002Fp>\n\n\u003Cp>University Center Lane, Suite 400\u003Cbr>\nSan Diego, CA 92122\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses www.ikconmedical.com and www.akcutestshop.com on February 3, 4, and 11, 2021. The FDA has observed that your website, www.akcutestshop.com, offers the “Akcutest COVID-19 Antibody Test” (also referred to as the “Akcutest Kit (25 tests per Kit $20\u002Ftest) COVID-19 Rapid Tests,” “Akcutest Sample Kit (3 tests per Kit $33\u002Ftest) COVID-19 Rapid tests,” and “Akcutest Serological Rapid Test”) (hereafter referred to as “Akcutest Kit”) and the “Lumigenik COVID-19 Antigen Rapid Test” (also referred to as “Lumigenik Sample Kit (3 tests per Kit $50\u002Ftest) COVID-19 Rapid Tests,” “Lumigenik Kit (25 tests per Kit $30\u002Ftest) COVID-19 Rapid Tests,” and “Lumigenik Antigen Rapid Test”) (hereafter referred to as “Lumigenik Kit”) for sale in the United States. Based on our review, these products&nbsp;are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The Akcutest Kit and the Lumigenik Kit are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>The Akcutest Kit is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to an establishment registration that create an impression of official FDA approval of the establishment or its products are misleading and constitute misbranding. See 21 CFR 807.39. Your websites reference FDA registration (e.g., “FDA registered”), at times incorporating unauthorized use of the FDA logo,\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> alongside information about and photos of the Akcutest Kit. As displayed, such representations imply that FDA has approved, cleared, authorized, or otherwise evaluated the product. As stated above, FDA has not approved, cleared, or authorized the product. Moreover, the “disclaimer” presented, for example, in small font and placed at the very bottom of your websites stating that “[t]his test has not been reviewed by the FDA” could be easily overlooked and does not mitigate the overall impression that FDA has approved, cleared, authorized, or otherwise evaluated the product. We also note that based on our review of FDA’s Establishment Registration &amp; Device Listing Database, an establishment with or including the name “Ikcon” is not registered and no device by the name of “Akcutest” was listed by any establishment. Therefore, statements indicating “FDA registered” also appear to be false. Your firm’s representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product(s) or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>.Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological\u003Cbr>\n&nbsp; &nbsp; Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca>https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRicardo Emmanuel Weichsel Upton\n\nRecipient Title\n\nPresident\n\nIkcon Investments, Inc dba Ikcon Medical\n\n14653 Caminito Lazanja\n\nSan Diego, CA 92127\n\nUnited States\n\ninfo@ikconmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: March 25, 2021\n\nTO:\n\n6540 Lusk Blvd Suite C-111\n\nSan Diego, CA 92121\n\nUniversity Center Lane, Suite 400\n\nSan Diego, CA 92122\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses www.ikconmedical.com and www.akcutestshop.com on February 3, 4, and 11, 2021. The FDA has observed that your website, www.akcutestshop.com, offers the “Akcutest COVID-19 Antibody Test” (also referred to as the “Akcutest Kit (25 tests per Kit $20\u002Ftest) COVID-19 Rapid Tests,” “Akcutest Sample Kit (3 tests per Kit $33\u002Ftest) COVID-19 Rapid tests,” and “Akcutest Serological Rapid Test”) (hereafter referred to as “Akcutest Kit”) and the “Lumigenik COVID-19 Antigen Rapid Test” (also referred to as “Lumigenik Sample Kit (3 tests per Kit $50\u002Ftest) COVID-19 Rapid Tests,” “Lumigenik Kit (25 tests per Kit $30\u002Ftest) COVID-19 Rapid Tests,” and “Lumigenik Antigen Rapid Test”) (hereafter referred to as “Lumigenik Kit”) for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe Akcutest Kit and the Lumigenik Kit are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nThe Akcutest Kit is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to an establishment registration that create an impression of official FDA approval of the establishment or its products are misleading and constitute misbranding. See 21 CFR 807.39. Your websites reference FDA registration (e.g., “FDA registered”), at times incorporating unauthorized use of the FDA logo,4 alongside information about and photos of the Akcutest Kit. As displayed, such representations imply that FDA has approved, cleared, authorized, or otherwise evaluated the product. As stated above, FDA has not approved, cleared, or authorized the product. Moreover, the “disclaimer” presented, for example, in small font and placed at the very bottom of your websites stating that “[t]his test has not been reviewed by the FDA” could be easily overlooked and does not mitigate the overall impression that FDA has approved, cleared, authorized, or otherwise evaluated the product. We also note that based on our review of FDA’s Establishment Registration & Device Listing Database, an establishment with or including the name “Ikcon” is not registered and no device by the name of “Akcutest” was listed by any establishment. Therefore, statements indicating “FDA registered” also appear to be false. Your firm’s representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product(s) or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products.Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological\n\nHealth\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n5 Accessible at https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Ikcon Investments, Inc dba Ikcon Medical","ikcon-investments-inc-dba-ikcon-medical-609791-03252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fikcon-investments-inc-dba-ikcon-medical-609791-03252021","2026-10-26T08:08:57.509369+00:00","2021-04-15","609791","Ricardo Emmanuel Weichsel Upton","2026-08-20T03:11:54.26+00:00","2021-03-25",{"id":51,"raw":52,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":20,"letter_url":63,"updated_at":64,"action_type":23,"case_status":24,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":20,"issuing_office":56,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":20,"reference_number":71,"action_taken_date":72,"medical_device_id":20,"response_letter_date":20},896,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwuxi-medical-instrument-factory-co-ltd-701044-04042025\">Wuxi Medical Instrument Factory Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-61\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chongjiu Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Wuxi Medical Instrument Factory Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No.43 Xixin Road, Zhangjing, Xibei Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wuxi Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>214194\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-25-61\u003C\u002Fp>\u003Cp>April 4, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Li:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Wuxi Medical Instrument Factory Co., Ltd., FEI 3006851654, located at No. 43 Xixin Road, Zhangjing, Xibei Town, Wuxi, from November 11 to 15, 2024.\u003C\u002Fp>\u003Cp>Because your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A).\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Inadequate Response\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your December 5, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you fail to provide adequate evidence of corrective actions taken to bring your operations into compliance with CGMP or confidence that you can manufacture sterile drugs. Your response notes that your “…company does not have the ability to pass FDA factory inspection and was not prepared to produce sterilized \u003Cstrong>(b)(4)\u003C\u002Fstrong> in accordance with the requirements of OCT [\u003Cem>sic\u003C\u002Fem>] Drug product so it does not produce sterilized \u003Cstrong>(b)(4)\u003C\u002Fstrong>, nor carry out the testing of sterility testing.” Drug manufacturers labeling their product as sterile must recognize the serious public health implications of distributing a non-sterile product, as it poses a significant health risk to patients.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Insanitary Conditions\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your drug products are adulterated under section 501(a)(2)(A) of the FD&amp;C Act because they were prepared, packed, or held under insanitary conditions whereby drugs may become contaminated with filth or rendered injurious to health. FDA investigators observed your facility to be in a state of disrepair, poorly cleaned, and maintained as evidenced by:\u003C\u002Fp>\u003Cul>\u003Cli>Numerous dead insects were inside the tubing used to transfer the active pharmaceutical ingredient (API), \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from storage drums to \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks, as well as a \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for storing API transfer hoses and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Multiple pieces of unknown debris in an \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution that was being \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a filling machine and transferred \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were packaged and labelled as sterile.\u003C\u002Fli>\u003Cli>Multiple pieces of tubing used to transfer \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution from holding containers to filling machines were cracked, leaking, discolored, or contained unidentified residues.\u003C\u002Fli>\u003Cli>Bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to make \u003Cstrong>(b)(4)\u003C\u002Fstrong> had hair, unknown particulates, or insects on them.\u003C\u002Fli>\u003Cli>The ceiling areas above uncovered filling and packaging machines used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> labelled as sterile were visibly dirty and damaged.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the insanitary conditions described above, FDA investigators observed during the inspection that since the previous inspection, your firm discontinued sterilization via \u003Cstrong>(b)(4)\u003C\u002Fstrong> without implementing a new sterilization procedure. Furthermore, your firm lacked a procedure for conducting environmental monitoring during manufacturing operations and failed to ensure operators adhered to proper gowning requirements, thereby compromising the sterility assurance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeled as sterile.\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made in the design and control of the aseptic processing operation.\u003C\u002Fli>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support-operations.\u003C\u002Fli>\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>A robust sterilization method and rigorous validation protocol that assures a sterility assurance level of 10-6 or more is achieved (e.g., provide F-value and Z-value data for any heat sterilization method), and uses an appropriate resistant biological indicator that represents the worst-case resistance of microbes that could be found in your environment and product. Include D-value determinations for each biological indicator lot to demonstrate its resistance to the specific sterilization method proposed for use by your firm.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile and pyrogen-free conforms to such requirements (21 CFR 211.167(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufactured and distributed an \u003Cstrong>(b)(4)\u003C\u002Fstrong> product labeled as \"sterile.\" However, you failed to perform sterility testing. It is essential that you conduct sterility testing on these and other purportedly sterile drugs prior to batch disposition decisions.\u003C\u002Fp>\u003Cp>In response to this letter, provide a list of chemical and microbial test methods and specifications used to analyze each batch of your drug product before making a batch disposition decision, and the associated written procedures.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm relied solely on certificates of analysis (COAs) for incoming lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, instead of conducting identity testing and verification for purity, strength, and quality or qualifying your component supplier. Additionally, your firm failed to test the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and microbial limits, despite its use in drug production. Without adequate testing, there is no assurance that these critical components meet required specifications before use in manufacturing. The failure to perform appropriate identity and testing raises concerns about product quality and associated potential risks to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date to your sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> despite having only \u003Cstrong>(b)(4)\u003C\u002Fstrong> of stability data. Additionally, your firm's procedure did not address ongoing stability testing to monitor your drug’s integrity throughout its shelf life. Without sufficient data, there is no assurance that your drug product maintains its identity, strength, quality, and purity for the full labeled expiration period.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On January 21, 2025, the FDA held a teleconference with you recommending you consider removing any batches of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> currently in distribution from the U.S. market.\u003C\u002Fp>\u003Cp>On February 11, 2025, you issued a voluntary recall of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to a lack of sterility assurance and CGMP violations observed during an inspection.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 21, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Wuxi Medical Instrument Factory Co., Ltd., Wuxi, China, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3006851654 and ATTN: Joseph Lambert, Pharm.D.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-61\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chongjiu Li\n\nRecipient Title\n\nGeneral Manager\n\nWuxi Medical Instrument Factory Co., Ltd.\n\nNo.43 Xixin Road, Zhangjing, Xibei Town\n\nWuxi Shi\n\nJiangsu Sheng, 214194\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-61\nApril 4, 2025\nDear Mr. Li:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Wuxi Medical Instrument Factory Co., Ltd., FEI 3006851654, located at No. 43 Xixin Road, Zhangjing, Xibei Town, Wuxi, from November 11 to 15, 2024.\nBecause your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A).\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nInadequate Response\nWe reviewed your December 5, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you fail to provide adequate evidence of corrective actions taken to bring your operations into compliance with CGMP or confidence that you can manufacture sterile drugs. Your response notes that your “…company does not have the ability to pass FDA factory inspection and was not prepared to produce sterilized (b)(4) in accordance with the requirements of OCT [sic] Drug product so it does not produce sterilized (b)(4), nor carry out the testing of sterility testing.” Drug manufacturers labeling their product as sterile must recognize the serious public health implications of distributing a non-sterile product, as it poses a significant health risk to patients.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\nInsanitary Conditions\nYour drug products are adulterated under section 501(a)(2)(A) of the FD&C Act because they were prepared, packed, or held under insanitary conditions whereby drugs may become contaminated with filth or rendered injurious to health. FDA investigators observed your facility to be in a state of disrepair, poorly cleaned, and maintained as evidenced by:\nNumerous dead insects were inside the tubing used to transfer the active pharmaceutical ingredient (API), (b)(4), from storage drums to (b)(4) tanks, as well as a (b)(4) used for storing API transfer hoses and (b)(4).\nMultiple pieces of unknown debris in an (b)(4) solution that was being (b)(4) to a filling machine and transferred (b)(4) that were packaged and labelled as sterile.\nMultiple pieces of tubing used to transfer (b)(4) solution from holding containers to filling machines were cracked, leaking, discolored, or contained unidentified residues.\nBulk (b)(4) of (b)(4) used to make (b)(4) had hair, unknown particulates, or insects on them.\nThe ceiling areas above uncovered filling and packaging machines used to manufacture (b)(4) labelled as sterile were visibly dirty and damaged.\nCGMP Violations\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\nIn addition to the insanitary conditions described above, FDA investigators observed during the inspection that since the previous inspection, your firm discontinued sterilization via (b)(4) without implementing a new sterilization procedure. Furthermore, your firm lacked a procedure for conducting environmental monitoring during manufacturing operations and failed to ensure operators adhered to proper gowning requirements, thereby compromising the sterility assurance of (b)(4) labeled as sterile.\nSee FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf.\nIn response to this letter, provide:\nComprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made in the design and control of the aseptic processing operation.\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support-operations.\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nA robust sterilization method and rigorous validation protocol that assures a sterility assurance level of 10-6 or more is achieved (e.g., provide F-value and Z-value data for any heat sterilization method), and uses an appropriate resistant biological indicator that represents the worst-case resistance of microbes that could be found in your environment and product. Include D-value determinations for each biological indicator lot to demonstrate its resistance to the specific sterilization method proposed for use by your firm.\n2. Your firm failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile and pyrogen-free conforms to such requirements (21 CFR 211.167(a)).\nYou manufactured and distributed an (b)(4) product labeled as \"sterile.\" However, you failed to perform sterility testing. It is essential that you conduct sterility testing on these and other purportedly sterile drugs prior to batch disposition decisions.\nIn response to this letter, provide a list of chemical and microbial test methods and specifications used to analyze each batch of your drug product before making a batch disposition decision, and the associated written procedures.\n3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm relied solely on certificates of analysis (COAs) for incoming lots of (b)(4), instead of conducting identity testing and verification for purity, strength, and quality or qualifying your component supplier. Additionally, your firm failed to test the (b)(4) system for (b)(4) and microbial limits, despite its use in drug production. Without adequate testing, there is no assurance that these critical components meet required specifications before use in manufacturing. The failure to perform appropriate identity and testing raises concerns about product quality and associated potential risks to patients.\nIn response to this letter, provide:\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour firm assigned a (b)(4) expiration date to your sterile (b)(4) despite having only (b)(4) of stability data. Additionally, your firm's procedure did not address ongoing stability testing to monitor your drug’s integrity throughout its shelf life. Without sufficient data, there is no assurance that your drug product maintains its identity, strength, quality, and purity for the full labeled expiration period.\nIn response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\nDrug Recall\nOn January 21, 2025, the FDA held a teleconference with you recommending you consider removing any batches of sterile (b)(4) currently in distribution from the U.S. market.\nOn February 11, 2025, you issued a voluntary recall of sterile (b)(4) due to a lack of sterility assurance and CGMP violations observed during an inspection.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 21, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Wuxi Medical Instrument Factory Co., Ltd., Wuxi, China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3006851654 and ATTN: Joseph Lambert, Pharm.D.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Wuxi Medical Instrument Factory Co., Ltd.","wuxi-medical-instrument-factory-co-ltd-701044-04042025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwuxi-medical-instrument-factory-co-ltd-701044-04042025","2026-10-26T08:10:33.535356+00:00","2025-05-20","701044","Drugs","Mr. Chongjiu Li","2026-08-19T16:46:55.829+00:00","VIA EMAIL WITH READ RECEIPT","320-25-61","2025-04-04",{"id":74,"raw":75,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":62,"fei_number":20,"letter_url":84,"updated_at":85,"action_type":23,"case_status":24,"posted_date":86,"marcs_cms_no":87,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":88,"body_fetched_at":89,"delivery_method":90,"recipient_title":20,"reference_number":20,"action_taken_date":91,"medical_device_id":20,"response_letter_date":20},875,[76,77,78,11,79,13,13,13],"\u003Ctime datetime=\"2025-05-27T04:00:00Z\">05\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-31T04:00:00Z\">03\u002F31\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrg-instruments-gmbh-700918-03312025\">DRG Instruments GmbH\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jörg Schlöβer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DRG Instruments GmbH\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Frauenbergstr. 18\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marburg\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>35039\u003C\u002Fspan> \u003Cspan>Hassia\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@drg-diagnostics.de\"> (b)(6)@drg-diagnostics.de  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Schlöβer:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Marburg, Germany on November 4 through 7, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in vitro diagnostic devices including the Salivary Cortisol ELISA (REF No. SLV-2930), the Salivary Testosterone ELISA, and the Salivary Cortisol ELISA RUO (REF No. SLV-2930R). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed evidence collected during the inspection and your firm’s website and determined that the Salivary Cortisol ELISA (REF No. SLV-2930) and Salivary Cortisol ELISA RUO (REF No. SLV-2930R) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Salivary Cortisol ELISA and Salivary Cortisol ELISA RUO are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these devices into commercial distribution, with major changes or modifications to the intended use, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>\u003Cu>Salivary Cortisol ELISA\u003C\u002Fu>\u003C\u002Fp>\u003Cp>You currently have clearance dated December 7, 2005, for a version of the Salivary Cortisol ELISA which was cleared under K051733 as a class II device under 21 CFR 862.1205 with the following indications:\u003C\u002Fp>\u003Cp>“An enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. Measurements of cortisol are used in the diagnosis and treatment of disorders of the adrenal gland.”\u003C\u002Fp>\u003Cp>However, as discussed in FDA’s Warning Letter dated September 19, 2017 issued to your firm, your firm has failed to submit a premarket notification submission to the Food and Drug Administration for significant changes that could significantly affect the safety or effectiveness of the device, as required by 21 CFR 807.81(a)(3)(i). As discussed in the 2017 Warning Letter, a new 510(k) is needed due to the use of a new monoclonal (mouse) antibody for the Salivary Cortisol ELISA. In addition, a new 510(k) is needed because of the change to the assay measuring range. As described in the FDA’s Decision Summary, the device that was reviewed and cleared by FDA under K051733 included 8 wells coated with rabbit anti-cortisol antiserum and had an assay measuring range of 0.537 - 80 ng\u002FmL. However, the package insert of the IVD-labeled Salivary Cortisol ELISA obtained during the 2024 inspection is described as containing microtiter wells that are coated with a monoclonal (mouse) antibody and the assay measuring range is described as 0.09 – 30 ng\u002FmL. The modified measuring range is narrower than the clinically relevant range. This change raises concerns that some patient samples with salivary cortisol higher than 30 ng\u002FmL may yield inaccurate results using the new assay which could place patients with normal cortisol levels at increased risk of misdiagnosis (e.g. elevated cortisol may be an indicator of Cushing Syndrome) or could lead to missed diagnosis of Cushing Syndrome if results are erroneously low. Such changes could significantly impact the safety and effectiveness of the device because such devices are often used in people with cortisol levels greater than 30 ng\u002FmL. Your firm was notified in the 2017 Warning Letter that the Salivary Cortisol ELISA devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated and that, as a result, FDA was taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations were corrected. To date, your firm has not received 510(k) clearance for your Salivary Cortisol ELISA devices that incorporate this significant change.\u003C\u002Fp>\u003Cp>\u003Cu>Salivary Cortisol ELISA RUO\u003C\u002Fu>\u003C\u002Fp>\u003Cp>The inspection revealed that your firm also markets and distributes the Salivary Cortisol ELISA RUO. Based on labeling collected during FDA’s inspection, the Salivary Cortisol ELISA RUO, like the Salivary Cortisol ELISA for in vitro diagnostic use, is designed to include monoclonal mouse antibodies and has an assay measuring range of 0.09 - 30 ng\u002FmL. Specifically, your firm's website www.drg-international.com describes the Salivary Cortisol ELISA RUO as “an enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva.”\u003C\u002Fp>\u003Cp>Based on evidence obtained during the inspection and a review of your firm’s website, the Salivary Cortisol ELISA RUO appears intended for clinical diagnostic use instead of for research use only. Such evidence includes:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm’s website includes product descriptions, images, and statements that suggest the Salivary Cortisol ELISA RUO device is intended for clinical diagnostic use. [https:\u002F\u002Fstore.drg-international.com\u002Fpc_product_detail.asp?key=2EAFBB068F3341EF8772F433DA7255B4]. For example:\u003Cbr>o A statement on your firm’s product page for the Salivary Cortisol ELISA RUO says that the “intensity of colour developed is inversely proportional to the concentration of cortisol in the patient sample.”\u003C\u002Fli>\u003Cli>Labeling collected during the inspection which your firm distributes with the Salivary Cortisol ELISA RUO device includes information that appears to conflict with RUO and suggests the device is actually intended for clinical diagnostic use despite the RUO labeling. For example:\u003Cbr>o The instructions for use that your firm distributes with the Salivary Cortisol ELISA RUO contains a specimen collection and preparation section that describes how samples should be collected from individuals (e.g. “Eating, drinking, chewing gums or brushing teeth should be avoided for 30 minutes before sampling.”) and gives directions on how saliva samples should be collected and over what time period to collect samples from individuals. The instructions for use also contain a Quality Control section which notes that “[a] statistically significant number of controls should be assayed to establish mean values and acceptable ranges to assure proper performance” and that users should ensure that assay results fit the established range of control materials or else be considered invalid. This type of language is typically included for IVDs that are intended for clinical diagnostic use, as this type of information is consistent with the prospective testing of patients and is not the type of information that is necessary for an assay in the laboratory research phase of development.\u003C\u002Fli>\u003Cli>A review of the customer records collected during the 2024 inspection shows that your firm sold and shipped Salivary Cortisol ELISA RUO to multiple companies in the business of performing clinical analysis. There is no indication that these companies also conduct research.\u003C\u002Fli>\u003Cli>Your firm’s website (last accessed March 11, 2025) https:\u002F\u002Fdrg-international.com\u002Fsalivary-elisa-kits\u002F describes the Salivary Cortisol ELISA RUO, along with other Salivary ELISA Kits, as having clear advantages, including:\u003Cbr>o “Simple, painless collection”\u003Cbr>o “Simple and patient-friendly measurement of hormone profiles”\u003Cbr>o “Can be performed also by patients”\u003Cbr>o “Easy sampling in babies and kids”\u003Cbr>o “Provides accurate, low level detection”\u003Cbr>o Clinical applications such as:\u003Cbr> “Diagnosis of systemic\u002Flocal conditions”\u003Cbr> Obstetrics &amp; Gynecology”\u003Cbr> “Drug Monitoring”\u003C\u002Fli>\u003Cli>Your firm’s website also provides a comparison of the Salivary Cortisol ELISA RUO to a reference test and states it provides “Industry Leading Accuracy with Kit Components Calibrated to Mass Spectrometry,” which implies that the Salivary Cortisol ELISA RUO is intended for clinical diagnostic use and not for research use only.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, during the inspection, your firm provided to the FDA investigator copies of certification letters from certain customers of the Salivary Cortisol ELISA RUO as evidence that these customers were aware that they were only supposed to use these products for research purposes. However, your firm admitted no such certification letter was received from one customer. A review of these customers’ websites strongly suggests that these customers are engaged in clinical diagnostic testing. As such, your statements that Salivary Cortisol ELISA RUO is intended for research use only are inconsistent with the evidence obtained during the inspection and the statements on your firm’s website, and FDA has determined that your Salivary Cortisol ELISA RUO is intended for clinical diagnostic use.\u003C\u002Fp>\u003Cp>Your Salivary Cortisol ELISA RUO appears to be intended for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. You were required to submit to FDA a 510(k) for this device, because either it is a new device (21 CFR 807.81(a)(1)) or, if your Salivary Cortisol ELISA RUO represents a change or modification from the device cleared in K051733, it has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Separately, we also note that your firm’s website includes a tab called “FDA Cleared Tests” (https:\u002F\u002Fdrg-international.com\u002F) and lists several devices for which there is no record of a 510(k) clearance held by your firm. For example, a Thyroid Stimulating Hormone (TSH) assay for in vitro diagnostic use is included on your firm’s website. However, a review of our records indicates that DRG Instruments does not have a 510(k) for a TSH assay. FDA requests that you review those devices listed under the “FDA Cleared Tests” tab on your website and either provide FDA with evidence that those devices are legally marketed or take corrective actions to address any additional uncleared devices marketed on your website.\u003C\u002Fp>\u003Cp>Further, during our review of your firm’s website (https:\u002F\u002Fdrg-international.com\u002Fhybrid-xl\u002F) we also noted that your firm states that DRG Hybrid XL is “Now FDA Approved” but also separately indicates that the DRG Hybrid XL is “FDA exempt for Class I.” We request that you clarify this statement on your website because indicating that a class I 510(k) exempt product has been reviewed and approved by FDA could be misleading. We request that your firm address these two additional issues in your response to this Warning Letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation (QSR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection also revealed that the devices manufactured in your facility are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Ina Hairston, U.S. Agent, DRG Instruments GmbH and Head of Regulatory Affairs, DRG International, Inc. dated November 26, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA No. 2024-14 was initiated July 1, 2024 due to a customer complaint of the low-level quality control for their Salivary Testosterone ELISA being invalid. However, your firm did not adequately investigate the cause of the nonconformity. Your firm confirmed the complaint by testing the remaining kits in inventory from two lots and found 21.3% (17 out of 80 bottles) of the low controls were out-of-specification (OOS). Your firm determined that the cause was due to the operator not washing the filling tube, nor discarding the first ten bottles, after switching from a higher to lower concentration of bulk solution, which were typical but not defined in the manufacturing procedure. Your firm's corrective action was to revise procedure aa-9131 to define a rinsing step and to require discarding of the first 20 bottles. However, the determined root cause of incomplete rinsing instructions does not demonstrate how such a lack of written procedures would reasonably be expected to result in 21.3% of retained low controls being OOS. Further, during the inspection, Mr. Polleichtner, Head of Quality Management &amp; Regulatory Affairs, indicated that there may be additional causes for the nonconformity and that your firm did not confirm that the operator failed to perform the rinse and discard step.\u003C\u002Fp>\u003Cp>The adequacy of the response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-22 and planned the following actions:\u003C\u002Fp>\u003Cul>\u003Cli>update of root cause analysis for CAPA 2024-14 by December 20, 2024;\u003C\u002Fli>\u003Cli>review of all open CAPAs and all CAPAs which actions are completed, but the effectiveness check is still pending regarding comprehensive root cause analysis by January 31, 2025; and\u003C\u002Fli>\u003Cli>update CAPAs identified to have inadequate root cause analysis to update the process of determining the root cause and affirm the root cause by February 28, 2025.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided. Additionally, your firm should provide a summary of the results of their retrospective review.\u003C\u002Fp>\u003Cp>2. Failure to adequately maintain records of complaint investigations that include required information, according to 21 CFR 820.198(e). For example, records of complaint investigations do not include required information, including any unique device identifier (UDI) or universal product code (UPC). Your firm's complaint records consistently did not include adequate contact information for the complainant, to include telephone number and address, and consistently did not include the Unique Device Identifier (UDI) code for the device which was the subject of the complaint. Specifically, complaint records for Complaint Nos. 47 and 49 do not list the complainant’s telephone number, complainant’s address, or the UDI code for the device.\u003C\u002Fp>\u003Cp>The adequacy of your firm's response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-24 and planned the following actions:\u003C\u002Fp>\u003Cul>\u003Cli>add UDI and contact information to all open complaint files by December 15, 2024;\u003C\u002Fli>\u003Cli>review of the complaint handling process and form regarding conformity with applicable regulations (EN ISO 13485, 21 CFR, IVDR) by December 15, 2024;\u003C\u002Fli>\u003Cli>file a change request based on finding(s) of complaint review process. At minimum, the requirement to provide the UDI\u002FUPC and complete customer contact information with every complaint is required by December 15, 2024;\u003C\u002Fli>\u003Cli>inform and provide immediate information to the complaint-handling personnel emphasizing the importance of recording complete information;\u003C\u002Fli>\u003Cli>review of Medical Device Single Audit Program (MDSAP) guidance documents, as these outline US-specific requirements, and are based on EN ISO 13485 by December 31, 2024;\u003C\u002Fli>\u003Cli>request implementation of gaps identified to the MDSAP guidance if applicable by January 10, 2025; and\u003C\u002Fli>\u003Cli>train revised documentation as required by January 31, 2025.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm identified the document titled “Reporting to Regulatory Authorities (and recall), Document aa-8.2.3.1, Revision 1, undated,” as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cul>\u003Cli>There is no evidence that the procedure has been implemented. For example, there is no effective date for your firm’s MDR procedure.\u003C\u002Fli>\u003Cli>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003Cbr>o The definition of the term “Reportable Event” in section 5 of your firm’s procedure only focuses on whether the device at issue would be likely to cause or contribute to a death or serious injury if the malfunction were to recur and does not include a consideration of whether a similar device marketed by your firm would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, as required in 21 CFR 803.3(o)(2)(ii).\u003Cbr>o The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fli>\u003Cli>The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the following are not addressed:\u003Cbr>o Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>o The circumstances under which your firm must submit an initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\u003Cbr>o How your firm will submit all information reasonably known to it for each event. Specifically, which sections of 3500A will need to be completed to include all the information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fli>\u003Cli>The procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>o Information that was evaluated to determine if an event was reportable.\u003Cbr>o Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable.\u003Cbr>o Systems that ensure access to information that facilitate timely follow-up and inspection by FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s procedure includes references to annual certifications. We note that annual certifications are no longer required, and we recommend that all references to an Annual Certification be removed from your firm’s MDR procedure. See 65 Fed. Reg. 4112 (Jan. 26, 2000). Furthermore, the procedure includes references to submit paper MDR reports. Please note, paper reports are generally no longer accepted from manufacturers and importers. See 21 CFR 803.11(a). The manufacturer is generally required to electronically submit MDRs following its established electronic submission process. 21 CFR 803.11(a).\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated November 26, 2024, cannot be determined at this time. The response notes that your firm plans to update its MDR procedure to include a reportability determination process, add evaluation recording process, and conduct staff training. However, your firm did not provide documentation or evidence demonstrating the implementation of these corrective actions, as they are still ongoing.\u003C\u002Fp>\u003Cp>We note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, the Salivary Cortisol ELISA and the Salivary Cortisol ELISA RUO devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as \"Detention Without Physical Examination of Devices without Approved PMA's or IDE's and Other Devices Not Substantially Equivalent or Without a 510(k),\" until these violations are addressed. To remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 700918 when replying. If you have any questions about the contents of this letter, please contact: Kimberly Mapp at Kimberly.mapp@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Ina Hairston\u003Cbr>U.S. Agent, DRG Instruments GmbH and\u003Cbr>Head of Regulatory Affairs, DRG International, Inc.\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>@drg-international.com\u003C\u002Fp>\u003Cp>Mr. Simon W. Huang, Chief Executive Officer\u003Cbr>BioCheck, Inc.\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>@biocheckinc.com\u003C\u002Fp>\u003Cp>Mr. Stephen A. Baliani, Comptroller\u003Cbr>DRG International, Inc.\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>@drg-international.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJörg Schlöβer\n\nRecipient Title\n\nManaging Director\n\nDRG Instruments GmbH\n\nFrauenbergstr. 18\n\nMarburg\n\n35039 Hassia\n\nGermany\n\n(b)(6)@drg-diagnostics.de\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2025\nDear Mr. Schlöβer:\nDuring an inspection of your firm located in Marburg, Germany on November 4 through 7, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in vitro diagnostic devices including the Salivary Cortisol ELISA (REF No. SLV-2930), the Salivary Testosterone ELISA, and the Salivary Cortisol ELISA RUO (REF No. SLV-2930R). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violations\nFDA has reviewed evidence collected during the inspection and your firm’s website and determined that the Salivary Cortisol ELISA (REF No. SLV-2930) and Salivary Cortisol ELISA RUO (REF No. SLV-2930R) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Salivary Cortisol ELISA and Salivary Cortisol ELISA RUO are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these devices into commercial distribution, with major changes or modifications to the intended use, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nSalivary Cortisol ELISA\nYou currently have clearance dated December 7, 2005, for a version of the Salivary Cortisol ELISA which was cleared under K051733 as a class II device under 21 CFR 862.1205 with the following indications:\n“An enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. Measurements of cortisol are used in the diagnosis and treatment of disorders of the adrenal gland.”\nHowever, as discussed in FDA’s Warning Letter dated September 19, 2017 issued to your firm, your firm has failed to submit a premarket notification submission to the Food and Drug Administration for significant changes that could significantly affect the safety or effectiveness of the device, as required by 21 CFR 807.81(a)(3)(i). As discussed in the 2017 Warning Letter, a new 510(k) is needed due to the use of a new monoclonal (mouse) antibody for the Salivary Cortisol ELISA. In addition, a new 510(k) is needed because of the change to the assay measuring range. As described in the FDA’s Decision Summary, the device that was reviewed and cleared by FDA under K051733 included 8 wells coated with rabbit anti-cortisol antiserum and had an assay measuring range of 0.537 - 80 ng\u002FmL. However, the package insert of the IVD-labeled Salivary Cortisol ELISA obtained during the 2024 inspection is described as containing microtiter wells that are coated with a monoclonal (mouse) antibody and the assay measuring range is described as 0.09 – 30 ng\u002FmL. The modified measuring range is narrower than the clinically relevant range. This change raises concerns that some patient samples with salivary cortisol higher than 30 ng\u002FmL may yield inaccurate results using the new assay which could place patients with normal cortisol levels at increased risk of misdiagnosis (e.g. elevated cortisol may be an indicator of Cushing Syndrome) or could lead to missed diagnosis of Cushing Syndrome if results are erroneously low. Such changes could significantly impact the safety and effectiveness of the device because such devices are often used in people with cortisol levels greater than 30 ng\u002FmL. Your firm was notified in the 2017 Warning Letter that the Salivary Cortisol ELISA devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated and that, as a result, FDA was taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations were corrected. To date, your firm has not received 510(k) clearance for your Salivary Cortisol ELISA devices that incorporate this significant change.\nSalivary Cortisol ELISA RUO\nThe inspection revealed that your firm also markets and distributes the Salivary Cortisol ELISA RUO. Based on labeling collected during FDA’s inspection, the Salivary Cortisol ELISA RUO, like the Salivary Cortisol ELISA for in vitro diagnostic use, is designed to include monoclonal mouse antibodies and has an assay measuring range of 0.09 - 30 ng\u002FmL. Specifically, your firm's website www.drg-international.com describes the Salivary Cortisol ELISA RUO as “an enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva.”\nBased on evidence obtained during the inspection and a review of your firm’s website, the Salivary Cortisol ELISA RUO appears intended for clinical diagnostic use instead of for research use only. Such evidence includes:\nYour firm’s website includes product descriptions, images, and statements that suggest the Salivary Cortisol ELISA RUO device is intended for clinical diagnostic use. [https:\u002F\u002Fstore.drg-international.com\u002Fpc_product_detail.asp?key=2EAFBB068F3341EF8772F433DA7255B4]. For example:\no A statement on your firm’s product page for the Salivary Cortisol ELISA RUO says that the “intensity of colour developed is inversely proportional to the concentration of cortisol in the patient sample.”\nLabeling collected during the inspection which your firm distributes with the Salivary Cortisol ELISA RUO device includes information that appears to conflict with RUO and suggests the device is actually intended for clinical diagnostic use despite the RUO labeling. For example:\no The instructions for use that your firm distributes with the Salivary Cortisol ELISA RUO contains a specimen collection and preparation section that describes how samples should be collected from individuals (e.g. “Eating, drinking, chewing gums or brushing teeth should be avoided for 30 minutes before sampling.”) and gives directions on how saliva samples should be collected and over what time period to collect samples from individuals. The instructions for use also contain a Quality Control section which notes that “[a] statistically significant number of controls should be assayed to establish mean values and acceptable ranges to assure proper performance” and that users should ensure that assay results fit the established range of control materials or else be considered invalid. This type of language is typically included for IVDs that are intended for clinical diagnostic use, as this type of information is consistent with the prospective testing of patients and is not the type of information that is necessary for an assay in the laboratory research phase of development.\nA review of the customer records collected during the 2024 inspection shows that your firm sold and shipped Salivary Cortisol ELISA RUO to multiple companies in the business of performing clinical analysis. There is no indication that these companies also conduct research.\nYour firm’s website (last accessed March 11, 2025) https:\u002F\u002Fdrg-international.com\u002Fsalivary-elisa-kits\u002F describes the Salivary Cortisol ELISA RUO, along with other Salivary ELISA Kits, as having clear advantages, including:\no “Simple, painless collection”\no “Simple and patient-friendly measurement of hormone profiles”\no “Can be performed also by patients”\no “Easy sampling in babies and kids”\no “Provides accurate, low level detection”\no Clinical applications such as:\n “Diagnosis of systemic\u002Flocal conditions”\n Obstetrics & Gynecology”\n “Drug Monitoring”\nYour firm’s website also provides a comparison of the Salivary Cortisol ELISA RUO to a reference test and states it provides “Industry Leading Accuracy with Kit Components Calibrated to Mass Spectrometry,” which implies that the Salivary Cortisol ELISA RUO is intended for clinical diagnostic use and not for research use only.\nIn addition, during the inspection, your firm provided to the FDA investigator copies of certification letters from certain customers of the Salivary Cortisol ELISA RUO as evidence that these customers were aware that they were only supposed to use these products for research purposes. However, your firm admitted no such certification letter was received from one customer. A review of these customers’ websites strongly suggests that these customers are engaged in clinical diagnostic testing. As such, your statements that Salivary Cortisol ELISA RUO is intended for research use only are inconsistent with the evidence obtained during the inspection and the statements on your firm’s website, and FDA has determined that your Salivary Cortisol ELISA RUO is intended for clinical diagnostic use.\nYour Salivary Cortisol ELISA RUO appears to be intended for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. You were required to submit to FDA a 510(k) for this device, because either it is a new device (21 CFR 807.81(a)(1)) or, if your Salivary Cortisol ELISA RUO represents a change or modification from the device cleared in K051733, it has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSeparately, we also note that your firm’s website includes a tab called “FDA Cleared Tests” (https:\u002F\u002Fdrg-international.com\u002F) and lists several devices for which there is no record of a 510(k) clearance held by your firm. For example, a Thyroid Stimulating Hormone (TSH) assay for in vitro diagnostic use is included on your firm’s website. However, a review of our records indicates that DRG Instruments does not have a 510(k) for a TSH assay. FDA requests that you review those devices listed under the “FDA Cleared Tests” tab on your website and either provide FDA with evidence that those devices are legally marketed or take corrective actions to address any additional uncleared devices marketed on your website.\nFurther, during our review of your firm’s website (https:\u002F\u002Fdrg-international.com\u002Fhybrid-xl\u002F) we also noted that your firm states that DRG Hybrid XL is “Now FDA Approved” but also separately indicates that the DRG Hybrid XL is “FDA exempt for Class I.” We request that you clarify this statement on your website because indicating that a class I 510(k) exempt product has been reviewed and approved by FDA could be misleading. We request that your firm address these two additional issues in your response to this Warning Letter.\nQuality System Regulation (QSR) Violations\nThis inspection also revealed that the devices manufactured in your facility are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ina Hairston, U.S. Agent, DRG Instruments GmbH and Head of Regulatory Affairs, DRG International, Inc. dated November 26, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA No. 2024-14 was initiated July 1, 2024 due to a customer complaint of the low-level quality control for their Salivary Testosterone ELISA being invalid. However, your firm did not adequately investigate the cause of the nonconformity. Your firm confirmed the complaint by testing the remaining kits in inventory from two lots and found 21.3% (17 out of 80 bottles) of the low controls were out-of-specification (OOS). Your firm determined that the cause was due to the operator not washing the filling tube, nor discarding the first ten bottles, after switching from a higher to lower concentration of bulk solution, which were typical but not defined in the manufacturing procedure. Your firm's corrective action was to revise procedure aa-9131 to define a rinsing step and to require discarding of the first 20 bottles. However, the determined root cause of incomplete rinsing instructions does not demonstrate how such a lack of written procedures would reasonably be expected to result in 21.3% of retained low controls being OOS. Further, during the inspection, Mr. Polleichtner, Head of Quality Management & Regulatory Affairs, indicated that there may be additional causes for the nonconformity and that your firm did not confirm that the operator failed to perform the rinse and discard step.\nThe adequacy of the response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-22 and planned the following actions:\nupdate of root cause analysis for CAPA 2024-14 by December 20, 2024;\nreview of all open CAPAs and all CAPAs which actions are completed, but the effectiveness check is still pending regarding comprehensive root cause analysis by January 31, 2025; and\nupdate CAPAs identified to have inadequate root cause analysis to update the process of determining the root cause and affirm the root cause by February 28, 2025.\nYour firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided. Additionally, your firm should provide a summary of the results of their retrospective review.\n2. Failure to adequately maintain records of complaint investigations that include required information, according to 21 CFR 820.198(e). For example, records of complaint investigations do not include required information, including any unique device identifier (UDI) or universal product code (UPC). Your firm's complaint records consistently did not include adequate contact information for the complainant, to include telephone number and address, and consistently did not include the Unique Device Identifier (UDI) code for the device which was the subject of the complaint. Specifically, complaint records for Complaint Nos. 47 and 49 do not list the complainant’s telephone number, complainant’s address, or the UDI code for the device.\nThe adequacy of your firm's response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-24 and planned the following actions:\nadd UDI and contact information to all open complaint files by December 15, 2024;\nreview of the complaint handling process and form regarding conformity with applicable regulations (EN ISO 13485, 21 CFR, IVDR) by December 15, 2024;\nfile a change request based on finding(s) of complaint review process. At minimum, the requirement to provide the UDI\u002FUPC and complete customer contact information with every complaint is required by December 15, 2024;\ninform and provide immediate information to the complaint-handling personnel emphasizing the importance of recording complete information;\nreview of Medical Device Single Audit Program (MDSAP) guidance documents, as these outline US-specific requirements, and are based on EN ISO 13485 by December 31, 2024;\nrequest implementation of gaps identified to the MDSAP guidance if applicable by January 10, 2025; and\ntrain revised documentation as required by January 31, 2025.\nYour firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm identified the document titled “Reporting to Regulatory Authorities (and recall), Document aa-8.2.3.1, Revision 1, undated,” as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\nThere is no evidence that the procedure has been implemented. For example, there is no effective date for your firm’s MDR procedure.\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\no The definition of the term “Reportable Event” in section 5 of your firm’s procedure only focuses on whether the device at issue would be likely to cause or contribute to a death or serious injury if the malfunction were to recur and does not include a consideration of whether a similar device marketed by your firm would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, as required in 21 CFR 803.3(o)(2)(ii).\no The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\nThe procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the following are not addressed:\no Instructions for how to obtain and complete the FDA 3500A form.\no The circumstances under which your firm must submit an initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\no How your firm will submit all information reasonably known to it for each event. Specifically, which sections of 3500A will need to be completed to include all the information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\nThe procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\no Information that was evaluated to determine if an event was reportable.\no Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable.\no Systems that ensure access to information that facilitate timely follow-up and inspection by FDA.\nYour firm’s procedure includes references to annual certifications. We note that annual certifications are no longer required, and we recommend that all references to an Annual Certification be removed from your firm’s MDR procedure. See 65 Fed. Reg. 4112 (Jan. 26, 2000). Furthermore, the procedure includes references to submit paper MDR reports. Please note, paper reports are generally no longer accepted from manufacturers and importers. See 21 CFR 803.11(a). The manufacturer is generally required to electronically submit MDRs following its established electronic submission process. 21 CFR 803.11(a).\nThe adequacy of your firm’s response dated November 26, 2024, cannot be determined at this time. The response notes that your firm plans to update its MDR procedure to include a reportability determination process, add evaluation recording process, and conduct staff training. However, your firm did not provide documentation or evidence demonstrating the implementation of these corrective actions, as they are still ongoing.\nWe note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\nGiven the serious nature of the violations of the Act, the Salivary Cortisol ELISA and the Salivary Cortisol ELISA RUO devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as \"Detention Without Physical Examination of Devices without Approved PMA's or IDE's and Other Devices Not Substantially Equivalent or Without a 510(k),\" until these violations are addressed. To remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 700918 when replying. If you have any questions about the contents of this letter, please contact: Kimberly Mapp at Kimberly.mapp@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nIna Hairston\nU.S. Agent, DRG Instruments GmbH and\nHead of Regulatory Affairs, DRG International, Inc.\n(b)(4)@drg-international.com\nMr. Simon W. Huang, Chief Executive Officer\nBioCheck, Inc.\n(b)(4), (b)(6)@biocheckinc.com\nMr. Stephen A. Baliani, Comptroller\nDRG International, Inc.\n(b)(4), (b)(6)@drg-international.com","DRG Instruments GmbH","drg-instruments-gmbh-700918-03312025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrg-instruments-gmbh-700918-03312025","2026-10-26T08:08:27.462903+00:00","2025-05-27","700918","Jörg Schlöβer","2026-08-19T16:44:15.579+00:00","VIA Electronic Mail","2025-03-31",{"id":93,"raw":94,"subject":57,"body_html":98,"body_text":99,"firm_name":100,"letter_id":101,"created_at":102,"fei_number":20,"letter_url":103,"updated_at":104,"action_type":23,"case_status":24,"posted_date":105,"marcs_cms_no":106,"product_type":67,"closeout_date":20,"issuing_office":56,"recipient_name":107,"body_fetched_at":108,"delivery_method":70,"recipient_title":20,"reference_number":20,"action_taken_date":109,"medical_device_id":20,"response_letter_date":20},1373,[95,96,97,56,57,13,13,13],"\u003Ctime datetime=\"2024-07-16T13:20:00Z\">07\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-08T04:00:00Z\">07\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyangzhou-suxiang-medical-instrument-co-ltd-686655-07082024\">YangZhou SuXiang Medical Instrument Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Bian Xiangli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>YangZhou SuXiang Medical Instrument Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>West of Baoyuan Road, Industrial Concentration Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Anyi Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baoying Xian\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-50\u003C\u002Fp>\n\n\u003Cp>July 8, 2024\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Xiangli:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 15, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, YangZhou SuXiang Medical Instrument Co., Ltd., 3014321771, at West of Baoyuan Road, Industrial Concentration Zone, Anyi Town, BaoYing County, Yangzhou City, China.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactured OTC drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong> Pads intended for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\n\n\u003Cp>The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document, \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol \u003C\u002Fem>at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information provided, you did not demonstrate that your manufacturing\u003Cbr>\nprocesses are reproducible and controlled to yield a product of uniform character and quality. For example, we requested the manufacturing process validation reports for your products. The reports you provided were incomplete. In addition, you distributed your products to U.S. markets prior to the performing process validations.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies includes intensive monitoring and testing of throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>We also note that your Quality Unit (QU) did not ensure that your manufacturing processes were adequately validated and in a state of control before releasing your OTC products for distribution to the U.S. market.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information provided, you did not demonstrate that you conducted adequate finished drug product testing on your drug products. For example, you did not provide analytical test data to demonstrate you adequately test products before releasing them for distribution.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on July 1, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at YangZhou SuXiang Medical Instrument Co., Ltd. at West of Baoyuan Road, Industrial Concentration Zone, Anyi Town, BaoYing County, Yangzhou City, Jiangsu Province, China into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014321771 and ATTN: Carlos Gonzalez.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Bian Xiangli\n\nRecipient Title\n\nManaging Director\n\nYangZhou SuXiang Medical Instrument Co., Ltd.\n\nWest of Baoyuan Road, Industrial Concentration Zone\n\nAnyi Town\n\nBaoying Xian\n\nYangzhou Shi\n\nJiangsu Sheng,\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-50\n\nJuly 8, 2024\n\nDear Mr. Xiangli:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 15, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, YangZhou SuXiang Medical Instrument Co., Ltd., 3014321771, at West of Baoyuan Road, Industrial Concentration Zone, Anyi Town, BaoYing County, Yangzhou City, China.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYour firm manufactured OTC drug products including (b)(4) Pads intended for (b)(4). Based on the records and information provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products.\n\nWithout adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\n\nThe use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document, Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\n2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nBased on the information provided, you did not demonstrate that your manufacturing\n\nprocesses are reproducible and controlled to yield a product of uniform character and quality. For example, we requested the manufacturing process validation reports for your products. The reports you provided were incomplete. In addition, you distributed your products to U.S. markets prior to the performing process validations.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies includes intensive monitoring and testing of throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWe also note that your Quality Unit (QU) did not ensure that your manufacturing processes were adequately validated and in a state of control before releasing your OTC products for distribution to the U.S. market.\n\n3. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nBased on the records and information provided, you did not demonstrate that you conducted adequate finished drug product testing on your drug products. For example, you did not provide analytical test data to demonstrate you adequately test products before releasing them for distribution.\n\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nCGMP Consultant Recommended\n\nIf your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on July 1, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at YangZhou SuXiang Medical Instrument Co., Ltd. at West of Baoyuan Road, Industrial Concentration Zone, Anyi Town, BaoYing County, Yangzhou City, Jiangsu Province, China into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014321771 and ATTN: Carlos Gonzalez.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","YangZhou SuXiang Medical Instrument Co., Ltd.","yangzhou-suxiang-medical-instrument-co-ltd-686655-07082024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyangzhou-suxiang-medical-instrument-co-ltd-686655-07082024","2026-10-26T08:10:36.044378+00:00","2024-07-16","686655","Mr. Bian Xiangli","2026-08-19T23:58:49.516+00:00","2024-07-08",{"id":111,"raw":112,"subject":57,"body_html":116,"body_text":117,"firm_name":118,"letter_id":119,"created_at":102,"fei_number":20,"letter_url":120,"updated_at":121,"action_type":23,"case_status":24,"posted_date":122,"marcs_cms_no":123,"product_type":67,"closeout_date":20,"issuing_office":56,"recipient_name":124,"body_fetched_at":125,"delivery_method":126,"recipient_title":20,"reference_number":127,"action_taken_date":128,"medical_device_id":20,"response_letter_date":20},1066,[113,114,115,56,57,13,13,13],"\u003Ctime datetime=\"2025-02-11T05:00:00Z\">02\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-30T05:00:00Z\">01\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrukmyer-llc-dba-strukmyer-medical-692686-01302025\">Strukmyer LLC dba Strukmyer Medical \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail Return Confirmation Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-37\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sudheer Kancherla\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Strukmyer LLC dba Strukmyer Medical \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1801 Big Town Blvd. Ste. 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mesquite\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75149-1011\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-37\u003C\u002Fp>\u003Cp>January 30, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Kancherla:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Strukmyer LLC dba Strukmyer Medical, FEI 3000205837, at 1801 Big Town Blvd. Ste. 100, Mesquite, TX, from July 8 to August 1, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On over 60 occasions, your firm isolated objectionable microorganisms (e.g., \u003Cem>Burkholderia, Pseudomonas, Staphylococcus, Bacillus\u003C\u002Fem>, and \u003Cem>Aspergillus\u003C\u002Fem> species) from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system used as a component to manufacture over-the-counter (OTC) drug products intended for use in wounds and on burns between November 1, 2022 and July 10, 2024. For example, Pseudomonas and Burkholderia were recovered from samples of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system on August 15 and August 21, 2023, respectively, and water from this system was used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on August 21, 2023. You failed to adequately investigate and implement corrective actions to determine root causes and prevent recurrence of these contamination incidents. We note that this drug product was previously the subject of a recall in 2020 for microbial contamination with \u003Cem>Burkholderia cepacia\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>In your response, you state that you updated your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water monitoring procedures to include specifications for the absence of objectionable organisms. You also state that you conducted an investigation into the implicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots and incidents of \u003Cem>Burkholderia\u003C\u002Fem> and \u003Cem>Pseudomonas\u003C\u002Fem> isolates in your water system and concluded there is no product impact because subsequent water samples collected at the time the water was used to manufacture the drug product were tested and results were observed to be within limits. Further, you state that your finished drug products met your microbial specifications.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your investigation did not adequately identify the root cause of the contamination of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system with objectionable microorganisms and failed to consider the impact to your distributed drug products that were manufactured with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water contaminated with objectionable microorganisms. Microbial contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. Frequent microbiological excursions suggest that your purified water system may not be in an adequate state of control.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fli>\u003Cli>All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate incoming testing of each component lot used in the manufacture of your OTC drug products, such as Therabreath Mild Mint Toothpaste intended for use in children. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you would update the specifications for your glycerin component to include identity testing, including DEG and EG testing, at a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing frequency. Additionally, you state that you tested retain sample of one glycerin lot from each \u003Cstrong>(b)(4)\u003C\u002Fstrong> since May 2023 to verify the quality of previously manufactured batches. You also committed to performing DEG and EG testing on the first lot of glycerin received each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to confirm the reliability of the testing results on the supplier’s COA.\u003C\u002Fp>\u003Cp>Your response is inadequate. CGMP requires that each shipment of each lot of a component undergo appropriate identity testing (which for glycerin, as noted above, includes a limit test for DEG and EG) before use in drug product manufacturing. Your response also did not include an evaluation of the quality of your drug products currently on the U.S market with inadequate component testing.\u003C\u002Fp>\u003Cp>Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before us in the manufacture of drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate your cleaning and disinfection practices are adequate to remove all contaminants from the equipment used to manufacture your topical OTC drug products. For example, your cleaning validation only tested for the absence of Gram-negative bacteria, but you have previously isolated fungi and gram-positive microorganisms from your water system.\u003C\u002Fp>\u003Cp>Inadequate removal of microbial organisms from manufacturing equipment during cleaning can result in contamination of your drug products, which can potentially cause patient harm depending on the organism.\u003C\u002Fp>\u003Cp>In your response, you committed to performing a new cleaning validation based on “worst-case” scenarios, including a toxicological and microbiological risk assessment of all raw materials using in manufacturing.\u003C\u002Fp>\u003Cp>Your response is inadequate in that the test methods appear to be incomplete.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to ensure the chemical and microbial testing methods performed by your contract laboratory for finished drug product release testing and water system monitoring were not adequately validated or verified as appropriate.\u003C\u002Fp>\u003Cp>In your response, you state that you sent drug product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples to your contract laboratory to complete method verification for your chemical and microbial tests. You also updated your procedure to require that method validations and verifications be performed on required test methods.\u003C\u002Fp>\u003Cp>Your response is inadequate. It did not provide assurance that the analytical test methods used to test your components and finished drug products are suitable for the intended purpose. Further, you did not provide an evaluation of potential impact to drug products currently on the U.S. market.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing quality systems and risk management approaches.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm to ensure you have an adequate contract testing facility are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your laboratory operations to evaluate adherence to appropriate practices.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health.\u003C\u002Fp>\u003Cp>Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000205837 and ATTN: Philip Kreiter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail Return Confirmation Requested\n\nReference #:\n\n320-25-37\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Sudheer Kancherla\n\nRecipient Title\n\nChief Executive Officer\n\nStrukmyer LLC dba Strukmyer Medical\n\n1801 Big Town Blvd. Ste. 100\n\nMesquite, TX 75149-1011\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-37\nJanuary 30, 2025\nDear Mr. Kancherla:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Strukmyer LLC dba Strukmyer Medical, FEI 3000205837, at 1801 Big Town Blvd. Ste. 100, Mesquite, TX, from July 8 to August 1, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nOn over 60 occasions, your firm isolated objectionable microorganisms (e.g., Burkholderia, Pseudomonas, Staphylococcus, Bacillus, and Aspergillus species) from your (b)(4) water system used as a component to manufacture over-the-counter (OTC) drug products intended for use in wounds and on burns between November 1, 2022 and July 10, 2024. For example, Pseudomonas and Burkholderia were recovered from samples of your (b)(4) water system on August 15 and August 21, 2023, respectively, and water from this system was used to manufacture (b)(4) batches (b)(4) and (b)(4) on August 21, 2023. You failed to adequately investigate and implement corrective actions to determine root causes and prevent recurrence of these contamination incidents. We note that this drug product was previously the subject of a recall in 2020 for microbial contamination with Burkholderia cepacia.\nIn your response, you state that you updated your (b)(4) water monitoring procedures to include specifications for the absence of objectionable organisms. You also state that you conducted an investigation into the implicated (b)(4) lots and incidents of Burkholderia and Pseudomonas isolates in your water system and concluded there is no product impact because subsequent water samples collected at the time the water was used to manufacture the drug product were tested and results were observed to be within limits. Further, you state that your finished drug products met your microbial specifications.\nYour response is inadequate. Your investigation did not adequately identify the root cause of the contamination of your (b)(4) water system with objectionable microorganisms and failed to consider the impact to your distributed drug products that were manufactured with (b)(4) water contaminated with objectionable microorganisms. Microbial contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\nInadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. Frequent microbiological excursions suggest that your purified water system may not be in an adequate state of control.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\nAppropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\nAll chemical and microbial test methods used to analyze each of your drug products.\nA summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate incoming testing of each component lot used in the manufacture of your OTC drug products, such as Therabreath Mild Mint Toothpaste intended for use in children. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\nGlycerin\nYou failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you state that you would update the specifications for your glycerin component to include identity testing, including DEG and EG testing, at a (b)(4) testing frequency. Additionally, you state that you tested retain sample of one glycerin lot from each (b)(4) since May 2023 to verify the quality of previously manufactured batches. You also committed to performing DEG and EG testing on the first lot of glycerin received each (b)(4) to confirm the reliability of the testing results on the supplier’s COA.\nYour response is inadequate. CGMP requires that each shipment of each lot of a component undergo appropriate identity testing (which for glycerin, as noted above, includes a limit test for DEG and EG) before use in drug product manufacturing. Your response also did not include an evaluation of the quality of your drug products currently on the U.S market with inadequate component testing.\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before us in the manufacture of drug products.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to demonstrate your cleaning and disinfection practices are adequate to remove all contaminants from the equipment used to manufacture your topical OTC drug products. For example, your cleaning validation only tested for the absence of Gram-negative bacteria, but you have previously isolated fungi and gram-positive microorganisms from your water system.\nInadequate removal of microbial organisms from manufacturing equipment during cleaning can result in contamination of your drug products, which can potentially cause patient harm depending on the organism.\nIn your response, you committed to performing a new cleaning validation based on “worst-case” scenarios, including a toxicological and microbiological risk assessment of all raw materials using in manufacturing.\nYour response is inadequate in that the test methods appear to be incomplete.\nIn response to this letter, provide:\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nYour quality unit (QU) failed to ensure the chemical and microbial testing methods performed by your contract laboratory for finished drug product release testing and water system monitoring were not adequately validated or verified as appropriate.\nIn your response, you state that you sent drug product and (b)(4) water samples to your contract laboratory to complete method verification for your chemical and microbial tests. You also updated your procedure to require that method validations and verifications be performed on required test methods.\nYour response is inadequate. It did not provide assurance that the analytical test methods used to test your components and finished drug products are suitable for the intended purpose. Further, you did not provide an evaluation of potential impact to drug products currently on the U.S. market.\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing quality systems and risk management approaches.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm to ensure you have an adequate contract testing facility are robust and appropriate.\no Provisions for QU oversight throughout your laboratory operations to evaluate adherence to appropriate practices.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health.\nSome conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000205837 and ATTN: Philip Kreiter.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________\n1 Components with higher risk of DEG or EG contamination compared to other drug components.","Strukmyer LLC dba Strukmyer Medical","strukmyer-llc-dba-strukmyer-medical-692686-01302025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrukmyer-llc-dba-strukmyer-medical-692686-01302025","2026-10-26T08:10:06.710761+00:00","2025-02-11","692686","Mr. Sudheer Kancherla","2026-08-19T17:02:33.632+00:00","Via Electronic Mail Return Confirmation Requested","320-25-37","2025-01-30",{"id":130,"raw":131,"subject":137,"body_html":138,"body_text":139,"firm_name":140,"letter_id":141,"created_at":142,"fei_number":20,"letter_url":143,"updated_at":144,"action_type":23,"case_status":145,"posted_date":146,"marcs_cms_no":147,"product_type":27,"closeout_date":148,"issuing_office":11,"recipient_name":149,"body_fetched_at":150,"delivery_method":151,"recipient_title":20,"reference_number":20,"action_taken_date":152,"medical_device_id":20,"response_letter_date":20},1660,[132,133,134,11,135,13,136,13],"\u003Ctime datetime=\"2024-01-09T14:20:00Z\">01\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-25T04:00:00Z\">08\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneitz-instruments-company-ltd-664336-08252023\">Neitz Instruments Company Ltd.\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneitz-instruments-company-ltd-664336-10022023\">\u003Ctime datetime=\"2024-02-28T05:00:00Z\">02\u002F28\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Takae Nishizawa\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Neitz Instruments Company Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4F Ichibancho Court 15-21\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ichibancho\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chiyoda-Ku JP-13\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>102-0082\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 25, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Ms. Nishizawa:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Ichibancho, Japan on May 15, 2023, through May 19, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Neitz Halogen Ophthalmoscope BXa, 13A Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, the following documents were presented as your firm’s MDR procedure.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Complaint Handling Procedure”, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 5\u002F27\u002F2022\u003C\u002Fli>\n\t\u003Cli>“Post-market Safety Control Operating Procedure”, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 11\u002F28\u002F2022\u003C\u002Fli>\n\t\u003Cli>“Corrective Action Procedure”, No Document Number, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 6\u002F30\u002F2022\u003C\u002Fli>\n\t\u003Cli>“Recall Procedure for Overseas Market”, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 3\u002F13\u002F2023\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>After collectively reviewing these documents, we determined that they do not contain information that would indicate that your MDR procedures created in accordance with the requirements in 21 CFR 803.17. Specifically,\u003C\u002Fp>\n\n\u003Cp>1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>\nb. The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>2. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\u003C\u002Fp>\n\n\u003Cp>a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The procedure, as written, does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\n\n\u003Cp>3. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. The circumstances under which your firm must submit initial (30 day) reports, supplemental\u002Ffollow-up reports, or 5-day reports, and the requirements for such reports.\u003Cbr>\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\u003Cbr>\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\n\n\u003Cp>4. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>\na. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\nb. Information that was evaluated to determine if an event was reportable.\u003Cbr>\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>Additionally, based on our records, as of July 14, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. Information about the ESG can be found at: \u003Cu>How to Enroll in eMDR Program | FDA\u003C\u002Fu>.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated June 16, 2023 and conclude that it is not adequate. The response notes that your firm is in the process of revising its procedures to incorporate the requirements of 21 CFR 803.17. Specifically, while it includes an excerpt of its revised procedure titled “Complaint and Quality Information Handling Procedure”, Rev. 14, and Section 5.3, which incorporates the definitions from 21 CFR 803.3 for the terms “MDR reportable event” and “serious injury,” it does not include additional definitions listed above. Furthermore, the additional deficiencies previously listed have not been addressed in your firm’s response.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to \u003Cu>CDRHWarningLetterResponses@fda.hhs.gov\u003C\u002Fu> or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. (Refer to CMS case # 664336 when replying). If you have any questions about the contents of this letter, please contact: Elvin Ng at 240-402-6195 or\u003Cbr>\nElvin.Ng@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>US AGENT:\u003C\u002Fstrong>\u003Cbr>\nTakahiro Haruyama\u003Cbr>\nGlobizz Corp.\u003Cbr>\n1411 W. 190th St., #200\u003Cbr>\nGardena, California 90248, U.S.A.\u003Cbr>\nEmail: Register@Globizz.Net\u003Cbr>\nPhone 1-310-538-3860\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Takae Nishizawa\n\nRecipient Title\n\nCEO\n\nNeitz Instruments Company Ltd.\n\n4F Ichibancho Court 15-21\n\nIchibancho\n\nChiyoda-Ku JP-13,\n\n102-0082\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nAugust 25, 2023\n\nDear Ms. Nishizawa:\n\nDuring an inspection of your firm located in Ichibancho, Japan on May 15, 2023, through May 19, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Neitz Halogen Ophthalmoscope BXa, 13A Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nOur inspection revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17\n\nFor example, during the inspection, the following documents were presented as your firm’s MDR procedure.\n\n“Complaint Handling Procedure”, (b)(4), dated 5\u002F27\u002F2022\n\n“Post-market Safety Control Operating Procedure”, (b)(4), dated 11\u002F28\u002F2022\n\n“Corrective Action Procedure”, No Document Number, (b)(4), dated 6\u002F30\u002F2022\n\n“Recall Procedure for Overseas Market”, (b)(4), dated 3\u002F13\u002F2023\n\nAfter collectively reviewing these documents, we determined that they do not contain information that would indicate that your MDR procedures created in accordance with the requirements in 21 CFR 803.17. Specifically,\n\n1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n2. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\n\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The procedure, as written, does not specify who makes the decision for reporting events to FDA.\n\n3. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. The circumstances under which your firm must submit initial (30 day) reports, supplemental\u002Ffollow-up reports, or 5-day reports, and the requirements for such reports.\n\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\n\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\n4. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nAdditionally, based on our records, as of July 14, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA.\n\nWe reviewed your firm’s response dated June 16, 2023 and conclude that it is not adequate. The response notes that your firm is in the process of revising its procedures to incorporate the requirements of 21 CFR 803.17. Specifically, while it includes an excerpt of its revised procedure titled “Complaint and Quality Information Handling Procedure”, Rev. 14, and Section 5.3, which incorporates the definitions from 21 CFR 803.3 for the terms “MDR reportable event” and “serious injury,” it does not include additional definitions listed above. Furthermore, the additional deficiencies previously listed have not been addressed in your firm’s response.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. (Refer to CMS case # 664336 when replying). If you have any questions about the contents of this letter, please contact: Elvin Ng at 240-402-6195 or\n\nElvin.Ng@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nUS AGENT:\n\nTakahiro Haruyama\n\nGlobizz Corp.\n\n1411 W. 190th St., #200\n\nGardena, California 90248, U.S.A.\n\nEmail: Register@Globizz.Net\n\nPhone 1-310-538-3860","Neitz Instruments Company Ltd.","neitz-instruments-company-ltd-664336-08252023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneitz-instruments-company-ltd-664336-08252023","2026-10-26T08:09:31.424756+00:00","Closed Out","2024-01-09","664336","2024-02-28","Ms. Takae Nishizawa","2026-08-20T00:23:19.157+00:00","Via Email","2023-08-25",{"id":154,"raw":155,"subject":161,"body_html":162,"body_text":163,"firm_name":164,"letter_id":165,"created_at":102,"fei_number":20,"letter_url":166,"updated_at":167,"action_type":23,"case_status":24,"posted_date":168,"marcs_cms_no":169,"product_type":27,"closeout_date":20,"issuing_office":170,"recipient_name":171,"body_fetched_at":172,"delivery_method":151,"recipient_title":20,"reference_number":20,"action_taken_date":173,"medical_device_id":20,"response_letter_date":20},1059,[156,157,158,159,160,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-21T05:00:00Z\">01\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobbins-instruments-llc-687984-01212025\">Robbins Instruments, LLC\u003C\u002Fa>","&quot;ORP: Office of Regulatory Programs, Office of Product Evaluation and Quality&quot;","Medical Device\u002FMisbranded\u002FUnapproved Device\u002FQuality System Regulation\u003Cbr \u002F>\r\n","Medical Device\u002FMisbranded\u002FUnapproved Device\u002FQuality System Regulation","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Phu N. Nguyen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Robbins Instruments, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2003 Edwards Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77007\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@robbinsinstruments.com\"> (b)(6)@robbinsinstruments.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"ORP: Office of Regulatory Programs, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS #687984\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 21, 2025\u003Cbr>\u003Cbr>Dear Mr. Nguyen:\u003Cbr>\u003Cbr>During an inspection of your firm located at 2003 Edwards Street, Houston, TX 77007, FEI 2221941, on March 27 through May 31, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of the Dermo-Jet Needleless Injector. &nbsp;Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved Device Violation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has learned that your firm is marketing the Dermo-Jet Needleless Injector without marketing clearance or approval, in violation of the Act. FDA has determined, based on information provided by your firm that the Dermo-Jet Needleless Injector is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Specifically, the instructions for use document for the Dermo-Jet Needleless Injector included in the company’s SOP document provided during the referenced inspection outlines the following indications: “The DERMO-JET is a versatile, time-tested, medical instrument for administration of sub-topical injections of parenteral medicaments, anesthetic solutions, steroids in aqueous suspension, soluble drugs, vaccines, antibiotics, etc.” &nbsp;\u003C\u002Fp>\u003Cp>In addition, the Robbins Instruments brochure for the DERMO-JET collected during the referenced inspection, includes many specific claims, as provided below:\u003C\u002Fp>\u003Cp>•&nbsp;&nbsp;&nbsp;&nbsp;“Painless Uses – A local Anesthetic prior to an injection using a syringe with a needle or a puncture (lumbar, pleural, articular, sternal, etc).\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Intradermic Injections and Tests – The reading of the result of the test is clear due to the absence of any secondary infection which might be caused by a needle.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Intradermic Vaccinations – BCG, Anti-cholera, Tetanus, Diphtheria, Whooping Cough, Measles.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Mesotherapy – Needleless injection can be given for intradermic treatment, local anesthetics or in connection with reflexology.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Dermatology – This method can be used for in situ injections in the treatment of alopecia, psoriasis, keloids and hypertrophic scars, sclerosis, keratosis, acne, etc.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Phlebology – Anesthetics prior to a thrombectomy and before hardening injections.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Urology – The treatment of Peyronie’s disease.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Proctology – The treatment of hemorrhoids.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Gynecology – Needleless injections of progesterone to regularize the ovarian cycles.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Minor Surgery – Painless suturing. By making contiguous papules one produces linear zones of anesthetic which help incision with a bistouri.\u003Cbr>•&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous Uses – Acupuncture, sports medicine, aesthetic medicine, etc.”\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at&nbsp;\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>FDA requests that Robbins Instruments, LLC cease any activities that result in the misbranding or adulteration of the Dermo-Jet Needleless Injector, such as the commercial distribution of the devices for the uses discussed above., including selling to initial importers, distributors, or other third parties for distribution and use within the United States or otherwise representing these devices to have the requisite clearance or authorization for marketing in the United States.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Danny Nguyen, Manager\u002FOwner on June 21, 2024, July 18, 2024, and August 15, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. &nbsp;These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1.&nbsp;&nbsp;&nbsp;&nbsp;Failure to review, evaluate and document the process and perform revalidation when changes or process deviations occurs, as required by 21 CFR 820.75(c).\u003C\u002Fp>\u003Cp>Specifically, your firm did not revalidate the changes made to your Dermo-Jet Needleless Injector Moist Heat Sterilization Method. You changed the sterilization process parameters from \u003Cem>134°C for 18 minutes\u003C\u002Fem> to \u003Cem>121°C\u002F250°F for 30 minutes\u003C\u002Fem> or \u003Cem>132°C\u002F270°F for 4 minutes\u003C\u002Fem> as identified in your product labeling IFU which you provide as cleaning and sterilization instructions to your customers. On August 23, 2019, your OEM Manufacturer validated the moist heat sterilization method under Study No. 1907-421 at \u003Cem>134°C for 18 minutes\u003C\u002Fem> but you altered the temperature and time limits without conducting revalidation of your new sterilization parameters. You have distributed approximately 400 Dermo-Jet Needleless Injectors to your customers with the updated cleaning and sterilization instructions. In addition, you have not established a process validation procedure required under 21 CFR Part 820.75(b). &nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that it is not adequate. Your firm submitted the sterilization validation report (High-power Study No. 1907-421) and a document change request form (DCR-01) dated 6\u002F27\u002F24 aimed at updating your moist heat sterilization specification to conform with the original sterilization parameters established by AKRA. It appears your firm has reverted to the moist heat sterilization parameters validated under study 1907-421, however, you have not addressed “Drying Time at minimum of 10 minutes” added to your Dermo-Jet Cleaning and Sterilization Sheet. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\u003C\u002Fp>\u003Cp>2.&nbsp;&nbsp;&nbsp;&nbsp;Failure to adequately establish design change procedures, as required by 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>Specifically, your firm has not established a design change procedure. &nbsp;Your firm updated the sterilization instruction in your instruction for use (IFU) without identification, documentation, validation or where appropriate verification, review and approval of design changes before their implementation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that it is not adequate. Your firm provided Biological Risk Assessment for the Dermo-jet HR (DOC ID BRA-0004-V1-EN-DEMJ) and a document change request (Form DCR-01); however, your firm has not provided design change procedures to ensure all your design change requirements can be met. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\u003C\u002Fp>\u003Cp>3.&nbsp;&nbsp;&nbsp;&nbsp;Failure to review, evaluate, and investigate complaints involving the possible failure of a device to meet any of its specifications where necessary, as required by 21 CFR 820.198(c).\u003C\u002Fp>\u003Cp>Specifically, your firm has not established a complaint handling procedure. Our investigator reviewed 31 complaint files and 23 of them were associated with failures of your Dermo-Jet Needleless Injectors in administering local anesthesia through intra-dermal injection to patients. &nbsp;For example, complaint\u002Frepair forms (SN45139, SN43812, and SN43824) pertain to your device failing to fire, penetrate, or inject medication as intended during operation. Your firm replaced the devices citing normal wear and tear from usage without investigating to determine whether the device, labeling, or its packaging failed to meet the product specifications.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that it is not adequate. Your firm submitted procedures for Medical Device Reporting requirements (Doc. No. MDRR0.001, Rev. 001) and the Complaint\u002FRepair Form (ROB-25). However, your procedure focuses on MDR reporting and does not incorporate a complaint handling process as required by 21 CFR 820.198. &nbsp; You have not provided corrections pertaining to your device’s failure to deliver medication as intended. &nbsp;You have not indicated your intention to conduct retrospective review of complaints to determine if an investigation is needed. &nbsp;In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\u003C\u002Fp>\u003Cp>4.&nbsp;&nbsp;&nbsp;&nbsp;Failure to establish device history record to demonstrate that the device was manufactured in accordance with the device master record, as required by 21 CFR 820.184.\u003C\u002Fp>\u003Cp>Specifically, your firm has not established procedures to ensure that device history records (DHRs) are properly maintained. Your firm stated the invoices of the assembled\u002Fmanufactured Dermo-Jet Needleless Injectors are your DHR. &nbsp;These invoices do not have the DHR elements outlined in Part 820.184, such as date of manufacture, quantity manufactured, quantity released for distribution, acceptance records, primary identification label and labeling used for production units. &nbsp;For example, your Dermo-Jet Needleless Injector acceptance records does not include testings performed such as rapidity, dosage size, reservoir capacity, weight, dimensions, etc. prior to final release. Your Dermo-Jet Design Specifications Sheet (#20) have these settings documented as design requirements for the proper functioning of your device.&nbsp;\u003Cbr>We reviewed your firm’s responses and conclude that it is not adequate. Your firm provided a Device History Record procedure (Doc. No. DHR.001, Rev. 001), however, there is no reference to acceptance records, such as testing for rapidity, dosage size, reservoir capacity, weight, and dimensions, to ensure device is manufactured in accordance with the DMR. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\u003C\u002Fp>\u003Cp>5.&nbsp;&nbsp;&nbsp;&nbsp;Failure to adequately document and maintain acceptance activities as part of the device history record, as required by 21 CFR 820.80(e).\u003C\u002Fp>\u003Cp>Specifically, your firm has not established procedures for acceptance activities such that inspections, tests, or other verification activities are performed to ensure compliance with specified requirements. The acceptance activities for receiving, in-process, and finished device acceptance are not documented in the DHR. &nbsp;For example, in-process activities such as the Ultrasonic Cleaner and Dryer Instrument times are not documented as stated by your Service Technicians and per your Dermo-Jet Assembly Procedure (#06). This equipment has not been validated.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that it is not adequate. Your firm provided your Acceptance Activity procedure (Doc. No. AAP.001, Ver. 001) outlining the process for accounting, verifying, and inspecting all incoming components. This procedure applies to components used to assemble or repair a Dermo-Jet device, but it does not adequately include provisions for inspection, testing, or other verification activities pertaining to finished devices. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\u003C\u002Fp>\u003Cp>6.&nbsp;&nbsp;&nbsp;&nbsp;Failure to establish procedures to control labeling activities, as required by 21 CFR 820.120.\u003C\u002Fp>\u003Cp>Specifically, your firm failed to define the requirements for conducting labeling reviews and overseeing labeling activities in your Labeling and Packing procedure (#10). For example, your procedure does not define how labels are printed and applied to remain legible and affixed during processing, storage, handling, and distribution; it does not define label\u002Flabeling inspection and release criteria; and it does not include labeling storage requirements for proper identification and is designed to prevent mix-ups. &nbsp;Your employee who prints and affixes label stated he does not review labels for content accuracy or assess if changes are made. &nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that it is not adequate. Your firm provided the Dermo-Jet Labeling procedure (Doc. No DL0.001, Ver 001) and a draft Dermo-Jet label as part of your corrective actions. Your procedure instructs that the Dermo-Jet boxes are labeled correctly to ensure that the UDI, serial number, lot number, and manufacturer information is affixed on all shipping boxes. However, your procedure lacks detail concerning label integrity, inspection of labels, and storage requirements to control labeling activities. Also, your draft Dermo-Jet label does not contain UDI information but a QR Code without any additional information. &nbsp;In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\u003C\u002Fp>\u003Cp>\u003Cstrong>Observations Pertaining to Other Regulations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Medical Device Reporting Violation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Dermo-Jet Needleless Injectors are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. &nbsp;Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm presented a two-page document titled “Summary of MDR Reporting Requirement for Manufacturers” as your written MDR procedure. However, upon review, it was determined that while the document references the 21 CFR 803.17 regulations, it does not provide information to demonstrate that it was developed as an MDR procedure in accordance with the requirements in 21 CFR 803.17.\u003C\u002Fp>\u003Cp>Additionally, your firm is recommended to establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of October 20, 2024, your firm does not have such an account. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated June 21, 2024, cannot be determined at this time. The response notes that your firm plans to develop a procedure to address the requirements of 21 CFR 803.17. However, no procedure was attached to the response, as the corrective action is still in progress.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated July 18, 2024, and conclude that it is not adequate. In the response, your firm includes a newly developed MDR procedure titled “MDR Reporting Requirements”, Document No. MDRR0.001, Version 001, dated July 9, 2024. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1.&nbsp;&nbsp;&nbsp;&nbsp;Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\u003C\u002Fp>\u003Cp>a.&nbsp;&nbsp;&nbsp;&nbsp;Your procedure omits definitions of the terms ‘become aware’, and ‘caused or contributed’, and the definition for the term ‘reasonably suggests’, found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).&nbsp;\u003Cbr>b.&nbsp;&nbsp;&nbsp;&nbsp;Your procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\u003Cp>2.&nbsp;&nbsp;&nbsp;&nbsp;Your procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, your procedure does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\u003Cp>3.&nbsp;&nbsp;&nbsp;&nbsp;Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include instructions for how to obtain the FDA 3500A form.\u003C\u002Fp>\u003Cp>4.&nbsp;&nbsp;&nbsp;&nbsp;Your procedure does not describe how your firm will address documentation and record keeping requirements, as required by 21 CFR 803.17(b), including:&nbsp;\u003Cbr>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>a.&nbsp;&nbsp;&nbsp;&nbsp;Documentation of adverse event related information maintained as MDR event files.&nbsp;\u003Cbr>b.&nbsp;&nbsp;&nbsp;&nbsp;Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>Additionally, your procedure includes a reference to submit MDRs to FDA via paper mail, and we recommend that all references to paper submissions be removed from your firm’s MDR procedure.&nbsp;\u003C\u002Fp>\u003Cp>Furthermore, your procedure includes a reference to submit a 10-workday report for reportable events involving death or serious injury. Please note that, under 21 CFR 803.10(c)(1), reports of death or serious injury must still be submitted within the 30-calendar days of the firm becoming aware of the event. We recommend your firm update the procedure to reflect the requirement.\u003C\u002Fp>\u003Cp>Your firm’s response dated August 15, 2024, did not provide any new information addressing the noted deficiencies.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranding under Section 502(t)(2) for Failure to Submit Required Information to GUDID\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The Dermo-Jet devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI.\u003C\u002Fp>\u003Cp>FDA has determined that your firm causes a label to be applied to Dermo-Jet devices with the intent that the devices will be commercially distributed without any subsequent replacement or modification of the label and\u002For causes the label of a device to be replaced or modified with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label (except that the addition of the name of, and contact information for, a person who distributes the device, without making any other changes to the label, is not a modification for the purposes of determining whether a person is a labeler). Robbins Instruments LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>Based on review of the Global Unique Device Identification Database (GUDID) on October 22, 2024, there are no entries for Robbins Instruments LLC or for devices with the trade names Dermo-Jet or any other injector associated with Robbins Instruments LLC. A search of GUDID was performed using the terms Robbins, Instruments, AKRA, Dermo-Jet, DJ05, injector, and KZE, and no relevant results were found. There are 32 entries in GUDID for the company name Robbins Instruments Inc, however none of the 32 entries is for the Dermo-Jet devices or any other injector.\u003C\u002Fp>\u003Cp>Your firm’s responses dated June 21, 2024, July 18, 2024, and August 15, 2024, are not adequate. Your firm’s response does not address GUDID reporting.\u003C\u002Fp>\u003Cp>\u003Cstrong>Medical Device Registration and Listing Violation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. &nbsp;In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. &nbsp;Our records indicate that your firm has not adequately fulfilled annual registration and listing requirements for fiscal year 2024.\u003C\u002Fp>\u003Cp>Therefore, all your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)). For example, the violation includes:\u003C\u002Fp>\u003Cp>Your firm is registered as an initial distributor\u002Fimporter for 2024, which does not align with your current type of operation. Our inspection revealed that your firm is engaged in manufacturing activities of your Dermo-Jet Needleless Injectors. Your firm is therefore required to annually register as a manufacturer and list the Dermo-Jet and other medical devices with the FDA.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003Cbr>\u003Cbr>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team Assistant Director, Jessica Mu, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, the CMS Case #687984 when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. &nbsp;Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>RDML Sean Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Device and Radiological Health\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPhu N. Nguyen\n\nRecipient Title\n\nManager\u002FOwner\n\nRobbins Instruments, LLC\n\n2003 Edwards Street\n\nHouston, TX 77007\n\nUnited States\n\n(b)(6)@robbinsinstruments.com\n\nIssuing Office:\n\n\"ORP: Office of Regulatory Programs, Office of Product Evaluation and Quality\"\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #687984\nJanuary 21, 2025\n\nDear Mr. Nguyen:\n\nDuring an inspection of your firm located at 2003 Edwards Street, Houston, TX 77007, FEI 2221941, on March 27 through May 31, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of the Dermo-Jet Needleless Injector. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violation\nFDA has learned that your firm is marketing the Dermo-Jet Needleless Injector without marketing clearance or approval, in violation of the Act. FDA has determined, based on information provided by your firm that the Dermo-Jet Needleless Injector is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nSpecifically, the instructions for use document for the Dermo-Jet Needleless Injector included in the company’s SOP document provided during the referenced inspection outlines the following indications: “The DERMO-JET is a versatile, time-tested, medical instrument for administration of sub-topical injections of parenteral medicaments, anesthetic solutions, steroids in aqueous suspension, soluble drugs, vaccines, antibiotics, etc.”\nIn addition, the Robbins Instruments brochure for the DERMO-JET collected during the referenced inspection, includes many specific claims, as provided below:\n• “Painless Uses – A local Anesthetic prior to an injection using a syringe with a needle or a puncture (lumbar, pleural, articular, sternal, etc).\n• Intradermic Injections and Tests – The reading of the result of the test is clear due to the absence of any secondary infection which might be caused by a needle.\n• Intradermic Vaccinations – BCG, Anti-cholera, Tetanus, Diphtheria, Whooping Cough, Measles.\n• Mesotherapy – Needleless injection can be given for intradermic treatment, local anesthetics or in connection with reflexology.\n• Dermatology – This method can be used for in situ injections in the treatment of alopecia, psoriasis, keloids and hypertrophic scars, sclerosis, keratosis, acne, etc.\n• Phlebology – Anesthetics prior to a thrombectomy and before hardening injections.\n• Urology – The treatment of Peyronie’s disease.\n• Proctology – The treatment of hemorrhoids.\n• Gynecology – Needleless injections of progesterone to regularize the ovarian cycles.\n• Minor Surgery – Painless suturing. By making contiguous papules one produces linear zones of anesthetic which help incision with a bistouri.\n• Miscellaneous Uses – Acupuncture, sports medicine, aesthetic medicine, etc.”\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nFDA requests that Robbins Instruments, LLC cease any activities that result in the misbranding or adulteration of the Dermo-Jet Needleless Injector, such as the commercial distribution of the devices for the uses discussed above., including selling to initial importers, distributors, or other third parties for distribution and use within the United States or otherwise representing these devices to have the requisite clearance or authorization for marketing in the United States.\nQuality System Regulation Violations\nOur inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Danny Nguyen, Manager\u002FOwner on June 21, 2024, July 18, 2024, and August 15, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to review, evaluate and document the process and perform revalidation when changes or process deviations occurs, as required by 21 CFR 820.75(c).\nSpecifically, your firm did not revalidate the changes made to your Dermo-Jet Needleless Injector Moist Heat Sterilization Method. You changed the sterilization process parameters from 134°C for 18 minutes to 121°C\u002F250°F for 30 minutes or 132°C\u002F270°F for 4 minutes as identified in your product labeling IFU which you provide as cleaning and sterilization instructions to your customers. On August 23, 2019, your OEM Manufacturer validated the moist heat sterilization method under Study No. 1907-421 at 134°C for 18 minutes but you altered the temperature and time limits without conducting revalidation of your new sterilization parameters. You have distributed approximately 400 Dermo-Jet Needleless Injectors to your customers with the updated cleaning and sterilization instructions. In addition, you have not established a process validation procedure required under 21 CFR Part 820.75(b).\nWe reviewed your firm’s responses and conclude that it is not adequate. Your firm submitted the sterilization validation report (High-power Study No. 1907-421) and a document change request form (DCR-01) dated 6\u002F27\u002F24 aimed at updating your moist heat sterilization specification to conform with the original sterilization parameters established by AKRA. It appears your firm has reverted to the moist heat sterilization parameters validated under study 1907-421, however, you have not addressed “Drying Time at minimum of 10 minutes” added to your Dermo-Jet Cleaning and Sterilization Sheet. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\n2. Failure to adequately establish design change procedures, as required by 21 CFR 820.30(i).\nSpecifically, your firm has not established a design change procedure. Your firm updated the sterilization instruction in your instruction for use (IFU) without identification, documentation, validation or where appropriate verification, review and approval of design changes before their implementation.\nWe reviewed your firm’s responses and conclude that it is not adequate. Your firm provided Biological Risk Assessment for the Dermo-jet HR (DOC ID BRA-0004-V1-EN-DEMJ) and a document change request (Form DCR-01); however, your firm has not provided design change procedures to ensure all your design change requirements can be met. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\n3. Failure to review, evaluate, and investigate complaints involving the possible failure of a device to meet any of its specifications where necessary, as required by 21 CFR 820.198(c).\nSpecifically, your firm has not established a complaint handling procedure. Our investigator reviewed 31 complaint files and 23 of them were associated with failures of your Dermo-Jet Needleless Injectors in administering local anesthesia through intra-dermal injection to patients. For example, complaint\u002Frepair forms (SN45139, SN43812, and SN43824) pertain to your device failing to fire, penetrate, or inject medication as intended during operation. Your firm replaced the devices citing normal wear and tear from usage without investigating to determine whether the device, labeling, or its packaging failed to meet the product specifications.\nWe reviewed your firm’s responses and conclude that it is not adequate. Your firm submitted procedures for Medical Device Reporting requirements (Doc. No. MDRR0.001, Rev. 001) and the Complaint\u002FRepair Form (ROB-25). However, your procedure focuses on MDR reporting and does not incorporate a complaint handling process as required by 21 CFR 820.198. You have not provided corrections pertaining to your device’s failure to deliver medication as intended. You have not indicated your intention to conduct retrospective review of complaints to determine if an investigation is needed. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\n4. Failure to establish device history record to demonstrate that the device was manufactured in accordance with the device master record, as required by 21 CFR 820.184.\nSpecifically, your firm has not established procedures to ensure that device history records (DHRs) are properly maintained. Your firm stated the invoices of the assembled\u002Fmanufactured Dermo-Jet Needleless Injectors are your DHR. These invoices do not have the DHR elements outlined in Part 820.184, such as date of manufacture, quantity manufactured, quantity released for distribution, acceptance records, primary identification label and labeling used for production units. For example, your Dermo-Jet Needleless Injector acceptance records does not include testings performed such as rapidity, dosage size, reservoir capacity, weight, dimensions, etc. prior to final release. Your Dermo-Jet Design Specifications Sheet (#20) have these settings documented as design requirements for the proper functioning of your device.\nWe reviewed your firm’s responses and conclude that it is not adequate. Your firm provided a Device History Record procedure (Doc. No. DHR.001, Rev. 001), however, there is no reference to acceptance records, such as testing for rapidity, dosage size, reservoir capacity, weight, and dimensions, to ensure device is manufactured in accordance with the DMR. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\n5. Failure to adequately document and maintain acceptance activities as part of the device history record, as required by 21 CFR 820.80(e).\nSpecifically, your firm has not established procedures for acceptance activities such that inspections, tests, or other verification activities are performed to ensure compliance with specified requirements. The acceptance activities for receiving, in-process, and finished device acceptance are not documented in the DHR. For example, in-process activities such as the Ultrasonic Cleaner and Dryer Instrument times are not documented as stated by your Service Technicians and per your Dermo-Jet Assembly Procedure (#06). This equipment has not been validated.\nWe reviewed your firm’s responses and conclude that it is not adequate. Your firm provided your Acceptance Activity procedure (Doc. No. AAP.001, Ver. 001) outlining the process for accounting, verifying, and inspecting all incoming components. This procedure applies to components used to assemble or repair a Dermo-Jet device, but it does not adequately include provisions for inspection, testing, or other verification activities pertaining to finished devices. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\n6. Failure to establish procedures to control labeling activities, as required by 21 CFR 820.120.\nSpecifically, your firm failed to define the requirements for conducting labeling reviews and overseeing labeling activities in your Labeling and Packing procedure (#10). For example, your procedure does not define how labels are printed and applied to remain legible and affixed during processing, storage, handling, and distribution; it does not define label\u002Flabeling inspection and release criteria; and it does not include labeling storage requirements for proper identification and is designed to prevent mix-ups. Your employee who prints and affixes label stated he does not review labels for content accuracy or assess if changes are made.\nWe reviewed your firm’s responses and conclude that it is not adequate. Your firm provided the Dermo-Jet Labeling procedure (Doc. No DL0.001, Ver 001) and a draft Dermo-Jet label as part of your corrective actions. Your procedure instructs that the Dermo-Jet boxes are labeled correctly to ensure that the UDI, serial number, lot number, and manufacturer information is affixed on all shipping boxes. However, your procedure lacks detail concerning label integrity, inspection of labels, and storage requirements to control labeling activities. Also, your draft Dermo-Jet label does not contain UDI information but a QR Code without any additional information. In response to this letter, please provide updates and supporting documentation of your corrective actions as they are implemented.\nObservations Pertaining to Other Regulations\nMedical Device Reporting Violation\nOur inspection also revealed that your firm’s Dermo-Jet Needleless Injectors are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm presented a two-page document titled “Summary of MDR Reporting Requirement for Manufacturers” as your written MDR procedure. However, upon review, it was determined that while the document references the 21 CFR 803.17 regulations, it does not provide information to demonstrate that it was developed as an MDR procedure in accordance with the requirements in 21 CFR 803.17.\nAdditionally, your firm is recommended to establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of October 20, 2024, your firm does not have such an account. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA.\nThe adequacy of your firm’s response dated June 21, 2024, cannot be determined at this time. The response notes that your firm plans to develop a procedure to address the requirements of 21 CFR 803.17. However, no procedure was attached to the response, as the corrective action is still in progress.\nWe reviewed your firm’s response dated July 18, 2024, and conclude that it is not adequate. In the response, your firm includes a newly developed MDR procedure titled “MDR Reporting Requirements”, Document No. MDRR0.001, Version 001, dated July 9, 2024. After reviewing the procedure, the following deficiencies were noted:\n1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\na. Your procedure omits definitions of the terms ‘become aware’, and ‘caused or contributed’, and the definition for the term ‘reasonably suggests’, found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. Your procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n2. Your procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, your procedure does not specify who makes the decision for reporting events to FDA.\n3. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include instructions for how to obtain the FDA 3500A form.\n4. Your procedure does not describe how your firm will address documentation and record keeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\nb. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\nAdditionally, your procedure includes a reference to submit MDRs to FDA via paper mail, and we recommend that all references to paper submissions be removed from your firm’s MDR procedure.\nFurthermore, your procedure includes a reference to submit a 10-workday report for reportable events involving death or serious injury. Please note that, under 21 CFR 803.10(c)(1), reports of death or serious injury must still be submitted within the 30-calendar days of the firm becoming aware of the event. We recommend your firm update the procedure to reflect the requirement.\nYour firm’s response dated August 15, 2024, did not provide any new information addressing the noted deficiencies.\nMisbranding under Section 502(t)(2) for Failure to Submit Required Information to GUDID\nThe Dermo-Jet devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI.\nFDA has determined that your firm causes a label to be applied to Dermo-Jet devices with the intent that the devices will be commercially distributed without any subsequent replacement or modification of the label and\u002For causes the label of a device to be replaced or modified with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label (except that the addition of the name of, and contact information for, a person who distributes the device, without making any other changes to the label, is not a modification for the purposes of determining whether a person is a labeler). Robbins Instruments LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nBased on review of the Global Unique Device Identification Database (GUDID) on October 22, 2024, there are no entries for Robbins Instruments LLC or for devices with the trade names Dermo-Jet or any other injector associated with Robbins Instruments LLC. A search of GUDID was performed using the terms Robbins, Instruments, AKRA, Dermo-Jet, DJ05, injector, and KZE, and no relevant results were found. There are 32 entries in GUDID for the company name Robbins Instruments Inc, however none of the 32 entries is for the Dermo-Jet devices or any other injector.\nYour firm’s responses dated June 21, 2024, July 18, 2024, and August 15, 2024, are not adequate. Your firm’s response does not address GUDID reporting.\nMedical Device Registration and Listing Violation\nUnder section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that your firm has not adequately fulfilled annual registration and listing requirements for fiscal year 2024.\nTherefore, all your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)). For example, the violation includes:\nYour firm is registered as an initial distributor\u002Fimporter for 2024, which does not align with your current type of operation. Our inspection revealed that your firm is engaged in manufacturing activities of your Dermo-Jet Needleless Injectors. Your firm is therefore required to annually register as a manufacturer and list the Dermo-Jet and other medical devices with the FDA.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team Assistant Director, Jessica Mu, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, the CMS Case #687984 when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\u002FS\u002F\nRDML Sean Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Device and Radiological Health","Robbins Instruments, LLC","robbins-instruments-llc-687984-01212025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobbins-instruments-llc-687984-01212025","2026-10-26T08:09:50.349018+00:00","2025-02-18","687984","\"ORP: Office of Regulatory Programs, Office of Product Evaluation and Quality\"","Phu N. Nguyen","2026-08-19T17:01:36.401+00:00","2025-01-21",{"id":175,"raw":176,"subject":137,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":62,"fei_number":20,"letter_url":184,"updated_at":185,"action_type":23,"case_status":24,"posted_date":186,"marcs_cms_no":187,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":188,"body_fetched_at":189,"delivery_method":151,"recipient_title":20,"reference_number":20,"action_taken_date":190,"medical_device_id":20,"response_letter_date":20},572,[177,178,179,11,137,13,13,13],"\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-23T04:00:00Z\">09\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finsung-medical-co-ltd-712545-09232025\">Insung Medical Co. Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. In-Keum Song\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer (CEO) \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Insung Medical Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>168 Gieopdosi-Ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jijeong-Myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wonju-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gangwon-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>26354\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:insungmedical@daum.net\"> insungmedical@daum.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 23, 2025\u003C\u002Fp>\u003Cp>Dear Mr. In-Keum Song:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Gangwon, Korea from April 28, 2025, through May 1, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures ANKOR Endobronchial Tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that your firm’s ANKOR Endobronchial Tubes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>The information included for Complaint ISQC‐22‐0513‐02 reasonably suggests that your firm’s ANKOR Endobronchial Tube malfunctioned (i.e. failure of carinal cuff to inflate) during the pre‐use check. Generally, a malfunction is reportable if, among other factors, the malfunction involves a device that is considered to be life‐supporting or life‐sustaining and thus is essential to maintaining human life. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63578, 63585 (Dec. 11, 1995). The fact that the malfunction occurred once leads to the presumption that the malfunction will recur. Your firm became aware of the referenced event on May 9, 2022. However, based on our records, the FDA has not received a corresponding malfunction report for the referenced event.\u003C\u002Fp>\u003Cp>Your firm’s responses dated May 19, 2025, and June 30, 2025, did not address the deficiency as it was not included on the FDA Form 483.\u003C\u002Fp>\u003Cp>2. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm presented a document “Medical Device Reporting Procedure (MDR)”, Document No.: MDR‐001~MDR‐003, Rev. 0, dated 2025‐01‐08, as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The procedure does not include the definitions for terms outlined at 21 CFR 803.3, including “become aware,” “caused or contributed,” “malfunction,” and “serious injury,\" and the definition for the term “reasonably suggests” found in 803.20(c)(1), which may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>2) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).\u003C\u002Fp>\u003Cp>Specifically, your procedure does not include:\u003C\u002Fp>\u003Cp>a. Instructions for how to complete the FDA 3500A form.\u003C\u002Fp>\u003Cp>b. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\u003C\u002Fp>\u003Cp>c. The circumstances under which your firm must submit supplement or follow-up report required under 21 CFR 803.56 and the requirements for such reports. Without such procedural instructions, your firm might fail to determine when supplemental reports are necessary, provide complete information, or comply with applicable reporting timeframes.\u003C\u002Fp>\u003Cp>Furthermore, it is recommended to establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of July 2, 2025, your firm does not have such an account. Information about the ESG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program.\u003C\u002Fp>\u003Cp>Your firm’s responses dated May 19, 2025, and June 30, 2025, did not address the procedural deficiencies as these were not included on the FDA Form 483.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Mr. Bradley Quinn at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS Case #712545, when replying. If you have any questions about the contents of this letter, please contact: Ms. Kimberly Miles at Kimberly.miles@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Kesia Alexander, Ph.D. Director&nbsp;\u003Cbr>OHT 1 Office of Office of Ophthalmic, Anesthesia,\u003Cbr>Respiratory, ENT and Dental Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. In-Keum Song\n\nRecipient Title\n\nPresident & Chief Executive Officer (CEO)\n\nInsung Medical Co. Ltd.\n\n168 Gieopdosi-Ro\n\nJijeong-Myeon\n\nWonju-si\n\nGangwon-do\n\n26354\n\nSouth Korea\n\ninsungmedical@daum.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nSeptember 23, 2025\nDear Mr. In-Keum Song:\nDuring an inspection of your firm located in Gangwon, Korea from April 28, 2025, through May 1, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures ANKOR Endobronchial Tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection revealed that your firm’s ANKOR Endobronchial Tubes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\n1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nThe information included for Complaint ISQC‐22‐0513‐02 reasonably suggests that your firm’s ANKOR Endobronchial Tube malfunctioned (i.e. failure of carinal cuff to inflate) during the pre‐use check. Generally, a malfunction is reportable if, among other factors, the malfunction involves a device that is considered to be life‐supporting or life‐sustaining and thus is essential to maintaining human life. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63578, 63585 (Dec. 11, 1995). The fact that the malfunction occurred once leads to the presumption that the malfunction will recur. Your firm became aware of the referenced event on May 9, 2022. However, based on our records, the FDA has not received a corresponding malfunction report for the referenced event.\nYour firm’s responses dated May 19, 2025, and June 30, 2025, did not address the deficiency as it was not included on the FDA Form 483.\n2. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm presented a document “Medical Device Reporting Procedure (MDR)”, Document No.: MDR‐001~MDR‐003, Rev. 0, dated 2025‐01‐08, as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n1) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The procedure does not include the definitions for terms outlined at 21 CFR 803.3, including “become aware,” “caused or contributed,” “malfunction,” and “serious injury,\" and the definition for the term “reasonably suggests” found in 803.20(c)(1), which may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n2) The MDR procedure, Rev. 0, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).\nSpecifically, your procedure does not include:\na. Instructions for how to complete the FDA 3500A form.\nb. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\nc. The circumstances under which your firm must submit supplement or follow-up report required under 21 CFR 803.56 and the requirements for such reports. Without such procedural instructions, your firm might fail to determine when supplemental reports are necessary, provide complete information, or comply with applicable reporting timeframes.\nFurthermore, it is recommended to establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of July 2, 2025, your firm does not have such an account. Information about the ESG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program.\nYour firm’s responses dated May 19, 2025, and June 30, 2025, did not address the procedural deficiencies as these were not included on the FDA Form 483.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Mr. Bradley Quinn at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS Case #712545, when replying. If you have any questions about the contents of this letter, please contact: Ms. Kimberly Miles at Kimberly.miles@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nKesia Alexander, Ph.D. Director\nOHT 1 Office of Office of Ophthalmic, Anesthesia,\nRespiratory, ENT and Dental Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Insung Medical Co. Ltd.","insung-medical-co-ltd-712545-09232025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finsung-medical-co-ltd-712545-09232025","2026-10-26T08:08:59.379658+00:00","2025-09-30","712545","Mr. In-Keum Song","2026-08-19T16:16:19.759+00:00","2025-09-23",{"id":192,"raw":193,"subject":197,"body_html":198,"body_text":199,"firm_name":200,"letter_id":201,"created_at":62,"fei_number":20,"letter_url":202,"updated_at":203,"action_type":23,"case_status":24,"posted_date":204,"marcs_cms_no":205,"product_type":67,"closeout_date":20,"issuing_office":56,"recipient_name":20,"body_fetched_at":206,"delivery_method":207,"recipient_title":20,"reference_number":20,"action_taken_date":208,"medical_device_id":20,"response_letter_date":20},591,[194,195,196,56,197,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025\">Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:https:\u002F\u002Fwww.getfitmedical.com\"> https:\u002F\u002Fwww.getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:drewcromer@getfitmedical.com\"> drewcromer@getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Get.Fit.Medical:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.\u003Ca id=\"footnoteref1_9e35aee\" href=\"#footnote1_9e35aee\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\u003Cbr>• “SILDENAFIL (GENERIC VIAGRA)”\u003Cbr>• “TADALAFIL (GENERIC CIALIS)”\u003Cbr>• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\u003Cbr>• “TIRZEPATIDE (GENERIC MOUNJARO)”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_gm2b1es\" href=\"#footnote2_gm2b1es\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_9e35aee\">\u003Ca href=\"#footnoteref1_9e35aee\">1\u003C\u002Fa>The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_gm2b1es\">\u003Ca href=\"#footnoteref2_gm2b1es\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nGet.Fit.Medical, LLC dba Get.Fit.Medical\n\nUnited States\n\nhttps:\u002F\u002Fwww.getfitmedical.com\n\ndrewcromer@getfitmedical.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nGet.Fit.Medical:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.1 As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\n• “SILDENAFIL (GENERIC VIAGRA)”\n• “TADALAFIL (GENERIC CIALIS)”\n• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\n• “TIRZEPATIDE (GENERIC MOUNJARO)”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Get.Fit.Medical, LLC dba Get.Fit.Medical","getfitmedical-llc-dba-getfitmedical-715801-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025","2026-10-26T08:08:45.732183+00:00","2025-09-16","715801","2026-08-19T16:21:40.471+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":210,"raw":211,"subject":79,"body_html":215,"body_text":216,"firm_name":217,"letter_id":218,"created_at":102,"fei_number":20,"letter_url":219,"updated_at":220,"action_type":23,"case_status":24,"posted_date":221,"marcs_cms_no":222,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":223,"body_fetched_at":224,"delivery_method":90,"recipient_title":20,"reference_number":20,"action_taken_date":225,"medical_device_id":20,"response_letter_date":20},1006,[212,213,214,11,79,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-21T05:00:00Z\">02\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fred-oak-instruments-llc-692368-02212025\">Red Oak Instruments, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. William C. Paske, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Red Oak Instruments, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3331 Prosperity Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Missouri City\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77459\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 692368\u003C\u002Fp>\u003Cp>February 21, 2025\u003C\u002Fp>\u003Cp>Mr. William C. Paske, PhD, Owner\u003Cbr>Red Oak Instruments, LLC\u003Cbr>3331 Prosperity Court\u003Cbr>Missouri City, TX 77459\u003C\u002Fp>\u003Cp>Dear Mr. Paske:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Red Oak Instruments, LLC (Red Oak, ROI, or “the firm”), located in Missouri City, Texas, on July 15, 2024, through July 26, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of the AC Powered Dynamometer RU-Fit (Model SR-3053) medical device. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these are devices intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>We received your responses dated August 13, 2024, November 7, 2024, and February 5, 2025 concerning our investigator’s observations on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded and\u002For Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed your website at https:\u002F\u002Fwww.redoakinstruments.com on January 15, 2025, and determined that the RU-FIT (Model SR-3053) is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The RU-FIT (Model SR-3053) is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>Devices classified under 21 CFR 888.1240 AC-powered dynamometer are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 886.9(a). However, there is evidence that the RU-FIT (Model SR-3053) is intended for uses that are different from those of legally marketed devices classified under 21 CFR 888.1240 AC-powered dynamometer. Generic devices of this type are intended “to assess neuromuscular function or degree of neuromuscular blockage by measuring, with a force transducer (a device that translates force into electrical impulses), the grip-strength of a patient's hand.” 21 CFR 888.1240 However, your firm is marketing the RU-FIT (Model SR-3053) for a different intended use, namely the device is intended to screen for possible mild traumatic brain injury (mTBI), also known as concussion.\u003C\u002Fp>\u003Cp>Examples include:\u003C\u002Fp>\u003Cp>\u003Cu>From the RU-Fit (Model SR-3053) User Guide\u003C\u002Fu>\u003Cbr>• This device is intended to screen for possible head injuries in the cases of head impact where there is not any visible blood, other than minor scraps [sic].\u003Cbr>• The SR-3053 should be used…to compare recognition and choice reaction times of an injured or non-injured individual.\u003C\u002Fp>\u003Cp>\u003Cu>From the RU-Fit (Model SR-3053) Training Presentation\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“Head Impact Trauma Screen: Analysis”\u003C\u002Fli>\u003Cli>“Recognition reaction times for the small, index fingers and thumb”\u003C\u002Fli>\u003Cli>“Cognitive reaction times for the small, index fingers and thumb”\u003C\u002Fli>\u003Cli>“Summary Sheet For Concussive Impact”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>From the Red Oak Instruments website (https:\u002F\u002Fwww.redoakinstruments.com)\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>Since denial is a strong symptom of mTBI subjects, the necessary compliance is not always achievable. A better technology is needed. RedOak Instruments provides the needed technology.\u003C\u002Fli>\u003Cli>Physicians, clinicians, military medics, emergency responders, coaches and trainers can now immediately evaluate the severity of a bloodless head injury on-site. This is especially important in the case of mTBI and other head injuries because denial of injury is a common reaction, and visible symptoms may be difficult to assess in the absence of visible blood such that the injury goes undetected.\u003C\u002Fli>\u003Cli>RedOak Instruments, LLC is a USA based biomechanical and software-based company which provides objective physiological measurements to screen for injuries, ailments and to monitor recovery. The test will document the reduction or improvement of factors related to head injury including fine motor control, coordination and reaction time.\u003C\u002Fli>\u003Cli>Additionally, ROI's RU-Fit model SR-3053 SensoKinetoGram offers objective monitoring for sports training programs to aid trainers and coaches as they develop and improve the coordination and reaction times of their athletes.&nbsp;\u003C\u002Fli>\u003Cli>Test the hands and protect the brain.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You state that “all systems are FDA cleared…” however you device is not cleared as presently marketed.\u003C\u002Fp>\u003Cp>Assessments of reaction time and cognitive function are not measurements of the grip-strength of a patient’s hand, and screening for, or detection of, mTBI is a neurological evaluation following head injury, not an assessment of neuromuscular function following hand injury.\u003C\u002Fp>\u003Cp>Further, we note that the RU-FIT (Model SR-3053) was previously cleared under K012492 with the following indications:\u003C\u002Fp>\u003Cp>Any situation where the hand grip or pinch strength would be a valuable piece of data in the evaluation of a person who has sustained an injury or suffers a disease of his\u002Fher hand(s).\u003C\u002Fp>\u003Cul>\u003Cli>To measure grip or pinch strength in an injured and uninjured hand.\u003C\u002Fli>\u003Cli>To conduct pre-employment screening for physically demanding job activities.\u003C\u002Fli>\u003Cli>To establish an industrial strength testing program in general, and to match the strength of workers to the strength demands of specific job duties in the workplace.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Thus, your firm’s promotion of the device provides evidence that the device is intended for to screen for possible mild traumatic brain injury (mTBI), also known as concussion, which would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm has failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the firm identified the document titled “Complaint MDR SOP ROI-000-0007,” dated 12\u002F11\u002F2019 as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\u003Cp>a. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms ‘become aware’, ‘caused or contributed’, ‘malfunction’, ‘MDR reportable event’, and ‘serious injury’, and the definition for the term ‘reasonably suggests’, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>b. Your procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\u003Cp>2. Your procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\u003C\u002Fp>\u003Cp>a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>b. Your procedure, as written, does not specify who makes the decision for reporting events to FDA.\u003Cbr>c. The flowchart in your firm’s procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\u003C\u002Fp>\u003Cp>3. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>b. The circumstances under which your firm must submit an initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\u003Cbr>c. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive. Information about the Final Rule for eMDR and the eMDR set-up process can be found on the FDA website at: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fmandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities\u002Femdr-electronic-medical-device-reporting\u003Cbr>d. How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\u003C\u002Fp>\u003Cp>4. Your procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\u003C\u002Fp>\u003Cp>a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>b. Information that was evaluated to determine if an event was reportable.\u003Cbr>c. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003Cbr>d. Systems that ensure access to information that facilitates timely follow-up and inspection by FDA.\u003C\u002Fp>\u003Cp>A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\u003Cp>Additionally, based on our records, as of October 29, 2024, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated August 13, 2024, cannot be determined at this time. Your firm’s response outlined plans to implement corrections and corrective actions, including creating an eMDR account and updating their MDR procedure. However, your firm did not provide documentation confirming the completion of these systemic corrective actions, including its revised MDR procedure, as they are still ongoing.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation (QSR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that the RU-Fit model SR-3053 is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish design change procedures as required by 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>Specifically, you did not document a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also did not document the design verification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\u003Cbr>The adequacy of your firm’s responses cannot be determined at this time. Your firm stated that it will update your Design Procedures to clarify when an ECO must be validated, or not, including training and that hardware changes will be documented that were not previously. You also state that you have rewritten your procedures, updated ECO forms, and “begun” documenting previously undocumented modifications. However, you have not provided evidence of corrective actions to show how you document design changes to ensure they are in compliance with 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>2. Failure of design verification to confirm that design output meets design input requirements as required by 21 CFR 820.30(f).\u003C\u002Fp>\u003Cp>Specifically, your firm lacks a Development Procedure Form to document design verification as required by section 9.3 of your Design Control procedure. Your firm did not document an update of acceptance limits for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> based on statistical test results in version 1.1 of your Test Plan.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm stated that it updated form ROI 001-0030-3 to show that the requisite measured uncertainties are within the specified range and that you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that multiple calibration tests were carried out to demonstrate stability and that \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications are in the DMR and components used in manufacturing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> are listed in the Inspection Acceptance Form. Your firm also stated it has \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm has not provided evidence of corrective actions to show how your design verification confirms that design output meets design input requirements.\u003C\u002Fp>\u003Cp>3. Failure to establish device acceptance procedures as required by 21 CFR 820.80(d).\u003C\u002Fp>\u003Cp>Specifically, you provided calibration test data but did not have a finished device acceptance procedure with complete product specifications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. You state that manufacturer certificates and testing data will be appended to calibration data, and you will confirm \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications. However, you have not provided evidence of corrective actions as to how you will develop and maintain a device acceptance procedure to ensure that each production run, lot, or batch of finished devices meets acceptance criteria.\u003C\u002Fp>\u003Cp>4. Failure to maintain device history record procedures as required by 21 CFR 820.184.\u003C\u002Fp>\u003Cp>Specifically, your Device History Record procedure states that you will record production run data, but you did not have such data for 107 RU-Fit devices you manufactured. You only had a bill of materials (BOM) provided as a Device Master Record (DMR).\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. You state that your data is available in excel charts and printed to pdf files. However, you have not provided evidence of the files stored electronically in your DMR folder.\u003C\u002Fp>\u003Cp>5. Failure to perform quality audits as required by 21 CFR 820.22.\u003C\u002Fp>\u003Cp>Specifically, your Internal Audit procedure states that you will conduct audits annually, but you did not have evidence of the performance of quality audits from 2018 to 2023.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. You state that you could not perform audits due to staffing and funding but that conducted an audit in December of 2024 and is in your form ROI 001-0024-0 as a pdf file. you will conduct and document an audit in 2024. However, you have not yet provided evidence of the conduct of the audit in December 2024.\u003C\u002Fp>\u003Cp>6. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency as required by 21 CFR 820.20(c).\u003C\u002Fp>\u003Cp>Specifically, your Management Responsibility procedure states that you will conduct reviews annually, but you did not have evidence of the performance of management reviews from 2018 to 2023.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. You state that you will update your Management Responsibility procedure and will conduct and document a review in 2024, including a minimum of one per quarter. However, you have not yet provided evidence of the conduct of your three review meetings stated as conducted since August 2024.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Jessica Mu, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS case #692368 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean Boyd, MPH, USPHS&nbsp;&nbsp;\u003Cbr>Director&nbsp;&nbsp;\u003Cbr>Office of Regulatory Programs&nbsp;&nbsp;\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. William C. Paske, PhD\n\nRecipient Title\n\nOwner\n\nRed Oak Instruments, LLC\n\n3331 Prosperity Court\n\nMissouri City, TX 77459\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 692368\nFebruary 21, 2025\nMr. William C. Paske, PhD, Owner\nRed Oak Instruments, LLC\n3331 Prosperity Court\nMissouri City, TX 77459\nDear Mr. Paske:\nDuring an inspection of your firm, Red Oak Instruments, LLC (Red Oak, ROI, or “the firm”), located in Missouri City, Texas, on July 15, 2024, through July 26, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of the AC Powered Dynamometer RU-Fit (Model SR-3053) medical device. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these are devices intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nWe received your responses dated August 13, 2024, November 7, 2024, and February 5, 2025 concerning our investigator’s observations on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\nMisbranded and\u002For Unapproved Device Violations\nFDA has reviewed your website at https:\u002F\u002Fwww.redoakinstruments.com on January 15, 2025, and determined that the RU-FIT (Model SR-3053) is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The RU-FIT (Model SR-3053) is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\nDevices classified under 21 CFR 888.1240 AC-powered dynamometer are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 886.9(a). However, there is evidence that the RU-FIT (Model SR-3053) is intended for uses that are different from those of legally marketed devices classified under 21 CFR 888.1240 AC-powered dynamometer. Generic devices of this type are intended “to assess neuromuscular function or degree of neuromuscular blockage by measuring, with a force transducer (a device that translates force into electrical impulses), the grip-strength of a patient's hand.” 21 CFR 888.1240 However, your firm is marketing the RU-FIT (Model SR-3053) for a different intended use, namely the device is intended to screen for possible mild traumatic brain injury (mTBI), also known as concussion.\nExamples include:\nFrom the RU-Fit (Model SR-3053) User Guide\n• This device is intended to screen for possible head injuries in the cases of head impact where there is not any visible blood, other than minor scraps [sic].\n• The SR-3053 should be used…to compare recognition and choice reaction times of an injured or non-injured individual.\nFrom the RU-Fit (Model SR-3053) Training Presentation\n“Head Impact Trauma Screen: Analysis”\n“Recognition reaction times for the small, index fingers and thumb”\n“Cognitive reaction times for the small, index fingers and thumb”\n“Summary Sheet For Concussive Impact”\nFrom the Red Oak Instruments website (https:\u002F\u002Fwww.redoakinstruments.com)\nSince denial is a strong symptom of mTBI subjects, the necessary compliance is not always achievable. A better technology is needed. RedOak Instruments provides the needed technology.\nPhysicians, clinicians, military medics, emergency responders, coaches and trainers can now immediately evaluate the severity of a bloodless head injury on-site. This is especially important in the case of mTBI and other head injuries because denial of injury is a common reaction, and visible symptoms may be difficult to assess in the absence of visible blood such that the injury goes undetected.\nRedOak Instruments, LLC is a USA based biomechanical and software-based company which provides objective physiological measurements to screen for injuries, ailments and to monitor recovery. The test will document the reduction or improvement of factors related to head injury including fine motor control, coordination and reaction time.\nAdditionally, ROI's RU-Fit model SR-3053 SensoKinetoGram offers objective monitoring for sports training programs to aid trainers and coaches as they develop and improve the coordination and reaction times of their athletes.\nTest the hands and protect the brain.\nYou state that “all systems are FDA cleared…” however you device is not cleared as presently marketed.\nAssessments of reaction time and cognitive function are not measurements of the grip-strength of a patient’s hand, and screening for, or detection of, mTBI is a neurological evaluation following head injury, not an assessment of neuromuscular function following hand injury.\nFurther, we note that the RU-FIT (Model SR-3053) was previously cleared under K012492 with the following indications:\nAny situation where the hand grip or pinch strength would be a valuable piece of data in the evaluation of a person who has sustained an injury or suffers a disease of his\u002Fher hand(s).\nTo measure grip or pinch strength in an injured and uninjured hand.\nTo conduct pre-employment screening for physically demanding job activities.\nTo establish an industrial strength testing program in general, and to match the strength of workers to the strength demands of specific job duties in the workplace.\nThus, your firm’s promotion of the device provides evidence that the device is intended for to screen for possible mild traumatic brain injury (mTBI), also known as concussion, which would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nMedical Device Reporting Violations\nOur inspection also revealed that your firm has failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the firm identified the document titled “Complaint MDR SOP ROI-000-0007,” dated 12\u002F11\u002F2019 as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\na. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms ‘become aware’, ‘caused or contributed’, ‘malfunction’, ‘MDR reportable event’, and ‘serious injury’, and the definition for the term ‘reasonably suggests’, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. Your procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n2. Your procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\nb. Your procedure, as written, does not specify who makes the decision for reporting events to FDA.\nc. The flowchart in your firm’s procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\n3. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\na. Instructions for how to obtain and complete the FDA 3500A form.\nb. The circumstances under which your firm must submit an initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive. Information about the Final Rule for eMDR and the eMDR set-up process can be found on the FDA website at: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fmandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities\u002Femdr-electronic-medical-device-reporting\nd. How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\n4. Your procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\na. Documentation of adverse event related information maintained as MDR event files.\nb. Information that was evaluated to determine if an event was reportable.\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\nd. Systems that ensure access to information that facilitates timely follow-up and inspection by FDA.\nA device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\nAdditionally, based on our records, as of October 29, 2024, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA.\nThe adequacy of your firm’s response dated August 13, 2024, cannot be determined at this time. Your firm’s response outlined plans to implement corrections and corrective actions, including creating an eMDR account and updating their MDR procedure. However, your firm did not provide documentation confirming the completion of these systemic corrective actions, including its revised MDR procedure, as they are still ongoing.\nQuality System Regulation (QSR) Violations\nOur inspection also revealed that the RU-Fit model SR-3053 is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n1. Failure to adequately establish design change procedures as required by 21 CFR 820.30(i).\nSpecifically, you did not document a (b)(4). You also did not document the design verification of the (b)(4).\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm stated that it will update your Design Procedures to clarify when an ECO must be validated, or not, including training and that hardware changes will be documented that were not previously. You also state that you have rewritten your procedures, updated ECO forms, and “begun” documenting previously undocumented modifications. However, you have not provided evidence of corrective actions to show how you document design changes to ensure they are in compliance with 21 CFR 820.30(i).\n2. Failure of design verification to confirm that design output meets design input requirements as required by 21 CFR 820.30(f).\nSpecifically, your firm lacks a Development Procedure Form to document design verification as required by section 9.3 of your Design Control procedure. Your firm did not document an update of acceptance limits for the (b)(4) based on statistical test results in version 1.1 of your Test Plan.\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm stated that it updated form ROI 001-0030-3 to show that the requisite measured uncertainties are within the specified range and that you (b)(4). Your firm stated that multiple calibration tests were carried out to demonstrate stability and that (b)(4) specifications are in the DMR and components used in manufacturing of (b)(4) are listed in the Inspection Acceptance Form. Your firm also stated it has (b)(4). However, your firm has not provided evidence of corrective actions to show how your design verification confirms that design output meets design input requirements.\n3. Failure to establish device acceptance procedures as required by 21 CFR 820.80(d).\nSpecifically, you provided calibration test data but did not have a finished device acceptance procedure with complete product specifications.\nThe adequacy of your firm’s responses cannot be determined at this time. You state that manufacturer certificates and testing data will be appended to calibration data, and you will confirm (b)(4) specifications. However, you have not provided evidence of corrective actions as to how you will develop and maintain a device acceptance procedure to ensure that each production run, lot, or batch of finished devices meets acceptance criteria.\n4. Failure to maintain device history record procedures as required by 21 CFR 820.184.\nSpecifically, your Device History Record procedure states that you will record production run data, but you did not have such data for 107 RU-Fit devices you manufactured. You only had a bill of materials (BOM) provided as a Device Master Record (DMR).\nThe adequacy of your firm’s responses cannot be determined at this time. You state that your data is available in excel charts and printed to pdf files. However, you have not provided evidence of the files stored electronically in your DMR folder.\n5. Failure to perform quality audits as required by 21 CFR 820.22.\nSpecifically, your Internal Audit procedure states that you will conduct audits annually, but you did not have evidence of the performance of quality audits from 2018 to 2023.\nThe adequacy of your firm’s responses cannot be determined at this time. You state that you could not perform audits due to staffing and funding but that conducted an audit in December of 2024 and is in your form ROI 001-0024-0 as a pdf file. you will conduct and document an audit in 2024. However, you have not yet provided evidence of the conduct of the audit in December 2024.\n6. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency as required by 21 CFR 820.20(c).\nSpecifically, your Management Responsibility procedure states that you will conduct reviews annually, but you did not have evidence of the performance of management reviews from 2018 to 2023.\nThe adequacy of your firm’s responses cannot be determined at this time. You state that you will update your Management Responsibility procedure and will conduct and document a review in 2024, including a minimum of one per quarter. However, you have not yet provided evidence of the conduct of your three review meetings stated as conducted since August 2024.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Jessica Mu, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS case #692368 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at raymond.brullo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nRDML Sean Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Red Oak Instruments, LLC","red-oak-instruments-llc-692368-02212025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fred-oak-instruments-llc-692368-02212025","2026-10-26T08:09:47.990114+00:00","2025-03-18","692368","Mr. William C. Paske, PhD","2026-08-19T16:56:33.784+00:00","2025-02-21",{"id":227,"raw":228,"subject":57,"body_html":233,"body_text":234,"firm_name":235,"letter_id":236,"created_at":142,"fei_number":20,"letter_url":237,"updated_at":238,"action_type":23,"case_status":24,"posted_date":239,"marcs_cms_no":240,"product_type":67,"closeout_date":20,"issuing_office":232,"recipient_name":241,"body_fetched_at":242,"delivery_method":243,"recipient_title":20,"reference_number":20,"action_taken_date":244,"medical_device_id":20,"response_letter_date":20},1603,[229,230,231,232,57,13,13,13],"\u003Ctime datetime=\"2024-02-13T14:20:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-01T05:00:00Z\">02\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmadhu-instruments-private-limited-659694-02012024\">Madhu Instruments Private Limited\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Amit Gupta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Madhu Instruments Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>A-260, Okhla Industrial Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phase-1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Delhi\u003C\u002Fspan> \u003Cspan>110020\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-19\u003C\u002Fp>\n\n\u003Cp>February 1, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gupta:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your manufacturing facility, Madhu Instruments Private Limited FEI 3007317099, at A-260, Okhla Industrial Area, Phase-1, New Delhi, from October 11 to 21, 2022.\u003C\u002Fp>\n\n\u003Cp>FDA determined that \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured at your facility are adulterated within the meaning of section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. 351(a)(2)(A), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth, or whereby they may have been rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 11, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Insanitary Conditions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators observed that products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your products to be adulterated under section 501(a)(2)(A) of the FD&amp;C Act. During the inspection, the investigators observed your manufacturing facility of products intended or expected to be sterile was in a state of disrepair, as noted by the following examples:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Peeling paint on the ceilings of your firm’s ISO 7 manufacturing rooms.\u003C\u002Fli>\n\t\u003Cli>A plastic bag covering the high efficiency particulate air (HEPA) filter in the manufacturing area impeding adequate airflow.\u003C\u002Fli>\n\t\u003Cli>Broken tiles along the base of the wall in the manufacturing rooms that were observed to have an \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue adhering to them. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> in color.\u003C\u002Fli>\n\t\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used to patch holes in the walls, and masking tape was used to secure \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to walls of the manufacturing rooms.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You do not have adequate controls in place to maintain a suitable production environment and prevent contamination of products manufactured at your facility. During the FDA inspection, your manufacturing equipment, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines were found to be visibly dirty and appeared to be stained with oil or grease residues. The cardboard box used to catch the product \u003Cstrong>(b)(4)\u003C\u002Fstrong> after \u003Cstrong>(b)(4)\u003C\u002Fstrong> is lined with white masking tape that has become stained and soiled over time. Additionally, the manual operation uses printer paper taped to the work surface on which filling and packaging of the products are performed.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledged that your cleaning and sanitization standard operating procedure (SOP) was inadequate, and your facility preventive maintenance plan was not implemented properly. You implemented a new checklist to verify and monitor cleaning and sanitization of the manufacturing areas and revised your SOPs for cleaning.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to conduct a retrospective review and assessment of the risks to product quality, including all potential contamination risks. Previously you had committed to improving your cleaning procedures but thus far have not adequately developed a cleaning and sanitization regimen that minimizes the risk of contamination. Although you terminally sterilize your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, it is imperative that you adequately design and maintain your facility to prevent the risk of adding contaminants, such as extraneous particulates, to your product.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan that assesses the vulnerabilities in your equipment cleaning and disinfection processes and practices, as well as facility and equipment design, which develops appropriate remediations to prevent contamination and provides timelines for completion.\u003C\u002Fli>\n\t\u003Cli>Your plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Documentation that supports your corrective actions such as work orders, room qualification, photos of any repairs your firm has made to correct the violation, and systemic plans to ensure the manufacturing areas remain adequately designed, controlled, and maintained.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on May 31, 2023.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of the products produced at your facility, FDA requests that you contact the Agency immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the FDA also allows you to meet any obligations you may have to report discontinuances or interruptions in your product manufacture under the FD&amp;C Act. This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any violations are completely addressed and we confirm your compliance with the Act. We may re-inspect to verify that you have completed corrective actions for any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Madhu Private Limited, A-260, Okhla Industrial Area, Phase-1, New Delhi, India, into the United States under section 801 of the FD&amp;C Act, 21 U.S.C. 381. Articles under this authority that appear to be adulterated or misbranded are subject to detention or refusal of admission.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007317099 and ATTN: Rokhsana Safaai-Jazi\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Amit Gupta\n\nRecipient Title\n\nDirector\n\nMadhu Instruments Private Limited\n\nA-260, Okhla Industrial Area\n\nPhase-1\n\nNew Delhi 110020\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWarning Letter 320-24-19\n\nFebruary 1, 2024\n\nDear Mr. Gupta:\n\nThe U.S. Food and Drug Administration (FDA) inspected your manufacturing facility, Madhu Instruments Private Limited FEI 3007317099, at A-260, Okhla Industrial Area, Phase-1, New Delhi, from October 11 to 21, 2022.\n\nFDA determined that (b)(4) manufactured at your facility are adulterated within the meaning of section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 351(a)(2)(A), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth, or whereby they may have been rendered injurious to health.\n\nWe reviewed your November 11, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with the FD&C Act.\n\nInsanitary Conditions\n\nFDA investigators observed that products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your products to be adulterated under section 501(a)(2)(A) of the FD&C Act. During the inspection, the investigators observed your manufacturing facility of products intended or expected to be sterile was in a state of disrepair, as noted by the following examples:\n\nPeeling paint on the ceilings of your firm’s ISO 7 manufacturing rooms.\n\nA plastic bag covering the high efficiency particulate air (HEPA) filter in the manufacturing area impeding adequate airflow.\n\nBroken tiles along the base of the wall in the manufacturing rooms that were observed to have an (b)(4) residue adhering to them. (b)(4) is (b)(4) in color.\n\nA (b)(4) was used to patch holes in the walls, and masking tape was used to secure (b)(4) and (b)(4) to walls of the manufacturing rooms.\n\nYou do not have adequate controls in place to maintain a suitable production environment and prevent contamination of products manufactured at your facility. During the FDA inspection, your manufacturing equipment, including (b)(4) machines were found to be visibly dirty and appeared to be stained with oil or grease residues. The cardboard box used to catch the product (b)(4) after (b)(4) is lined with white masking tape that has become stained and soiled over time. Additionally, the manual operation uses printer paper taped to the work surface on which filling and packaging of the products are performed.\n\nIn your response, you acknowledged that your cleaning and sanitization standard operating procedure (SOP) was inadequate, and your facility preventive maintenance plan was not implemented properly. You implemented a new checklist to verify and monitor cleaning and sanitization of the manufacturing areas and revised your SOPs for cleaning.\n\nYour response is inadequate because you failed to conduct a retrospective review and assessment of the risks to product quality, including all potential contamination risks. Previously you had committed to improving your cleaning procedures but thus far have not adequately developed a cleaning and sanitization regimen that minimizes the risk of contamination. Although you terminally sterilize your (b)(4), it is imperative that you adequately design and maintain your facility to prevent the risk of adding contaminants, such as extraneous particulates, to your product.\n\nIn response to this letter, provide the following:\n\nYour plan that assesses the vulnerabilities in your equipment cleaning and disinfection processes and practices, as well as facility and equipment design, which develops appropriate remediations to prevent contamination and provides timelines for completion.\n\nYour plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nDocumentation that supports your corrective actions such as work orders, room qualification, photos of any repairs your firm has made to correct the violation, and systemic plans to ensure the manufacturing areas remain adequately designed, controlled, and maintained.\n\nConclusion\n\nFDA placed your firm on Import Alert 66-40 on May 31, 2023.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of the products produced at your facility, FDA requests that you contact the Agency immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the FDA also allows you to meet any obligations you may have to report discontinuances or interruptions in your product manufacture under the FD&C Act. This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any violations are completely addressed and we confirm your compliance with the Act. We may re-inspect to verify that you have completed corrective actions for any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Madhu Private Limited, A-260, Okhla Industrial Area, Phase-1, New Delhi, India, into the United States under section 801 of the FD&C Act, 21 U.S.C. 381. Articles under this authority that appear to be adulterated or misbranded are subject to detention or refusal of admission.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007317099 and ATTN: Rokhsana Safaai-Jazi\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Madhu Instruments Private Limited","madhu-instruments-private-limited-659694-02012024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmadhu-instruments-private-limited-659694-02012024","2026-10-26T08:09:18.175339+00:00","2024-02-13","659694","Mr. Amit Gupta","2026-08-20T00:18:28.461+00:00","VIA UPS","2024-02-01",{"id":246,"raw":247,"subject":251,"body_html":252,"body_text":253,"firm_name":254,"letter_id":255,"created_at":256,"fei_number":20,"letter_url":257,"updated_at":258,"action_type":23,"case_status":24,"posted_date":259,"marcs_cms_no":260,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":261,"body_fetched_at":262,"delivery_method":90,"recipient_title":20,"reference_number":20,"action_taken_date":263,"medical_device_id":20,"response_letter_date":20},247,[248,249,250,11,251,13,13,13],"\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-12T05:00:00Z\">11\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphysitemp-instruments-llc-717394-11122025\">Physitemp Instruments, LLC\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michele J. Cantwell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Sales and Marketing \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Physitemp Instruments, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>189 Sargeant Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clifton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07013\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 717394\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 12, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Cantwell:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Clifton, NJ from April 29, 2025 through June 18, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and a Needle Microprobe (MT-D). These products are intended to measure human body temperature in clinical settings, for example, profiling tumor temperature during cancer hyperthermia and measuring myocardial temperature during bypass surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Yirelisa Alcantara, Quality Assurance Regulatory Coordinator, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for process validation. For example, the following processes were not validated or adequately validated to ensure your Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) and Needle Microprobe (MT-D) meet pre-determined specifications for sterility and laser welding:\u003C\u002Fp>\u003Cp>A. \u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> Sterilization\u003C\u002Fu>\u003Cbr>You have not conducted validations of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization method documented in the respective sterilization guides you supply to customers for sterilization of your esophageal (ESO-1) and rectal (RET-1) Clinical Temperature Monitoring Probes and Needle Microprobe (MT-D) to ensure they consistently produce product that meets pre-determined specifications for sterility.\u003C\u002Fp>\u003Cp>Moreover, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterility Tests for “Mixed Skin Sensors” and “Skin Sensors” conducted between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are inadequate because you were unable to provide objective evidence that the study included the current versions of your clinical skin sensor Clinical Temperature Monitoring Probes (SST-1 and SST-2) as well as other information such as (but not limited to) load configurations and raw data.\u003C\u002Fp>\u003Cp>B. \u003Cu>Laser Welding\u003C\u002Fu>\u003Cbr>Your installation qualifications titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Installation Qualification” (Rev A; Effective: 4\u002F29\u002F24) and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Operation Qualification” (Rev A; Effective: 4\u002F29\u002F24) are incomplete because they failed to ensure that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Model #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>; SN #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>), used to weld thermocouple wires of your Clinical Temperature Monitoring Probes and Needle Microprobe (MT-D), was installed in accordance with the manufacturer’s electrical requirements for input power voltage and grounding, as described in the “start preparing” section of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> User Manual. Furthermore, you have not conducted a validation of your laser welding process to ensure it consistently produces product that meets pre-determined specifications for weldin\u003Ca>g.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In response to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation, you state that the formal \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation for skin sensor probes was provided to the investigator during the inspection. However, these studies were found to be inadequate because you were unable to provide objective evidence that they included the current versions of your Clinical Temperature Monitoring Probes (SST-1 and SST-2) as well as other information such as (but not limited to) load configurations and raw data. Overall, your response failed to include any corrective actions to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validations for your Clinical Temperature Monitoring Probes and Needle Microprobe (MT-D) which are intended for human use.\u003C\u002Fp>\u003Cp>In response to the laser welding validation, you state that there was a mix-up in the documentation that was provided to the investigator and that the current in use laser welder is the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, not the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, this contradicts the effective dates of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Installation Qualification” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Operation Qualification” which were provided to the investigator during the inspection which point to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Welder as the equipment in current use. Under CAPA-25-003, you removed all legacy material for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your corrective actions are to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. By \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there were no corrective actions identified to define and document an overarching procedure to conduct process validations, with a high degree of assurance, to ensure that your processes consistently produce products that meets pre-determined specifications at worst case and nominal operating parameters.\u003C\u002Fp>\u003Cp>In your response, you also point out that the requirements of 21 CFR 820.75(a) with regards to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation for the Implantable Temperature Monitoring Probes (IT-14; IT-18 series; IT-21; IT-23; IT-IE) do not apply because these probes are primarily used in general laboratory research applications such as liquid vials, tissue culture, ex-vivo tissue samples, and subcutaneous use in living research animals and not human use. Under CAPA 25-007, you reviewed all labeling (e.g., instructions, promotional materials, etc.) for the Implantable Temperature Monitoring Probes and communicated the intended use to the sales and customer support teams. The corrective actions are to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you have not identified whether any actions should be taken that are commensurate with the risk of customers using the Implantable Temperature Monitoring Probes already in the field on humans due to ambiguous labeling and for which no \u003Cstrong>(b)(4)\u003C\u002Fstrong>, autoclaving, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, hermetic sealing, or laser welding validations were conducted. During correspondence with a customer between \u003Cstrong>(b)(4)\u003C\u002Fstrong>, through \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you received a complaint (# 9462) for a broken wire and battery box for the IT-18EXLONG (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) Implantable Temperature Monitoring Probe with a request for replacement “***\u003Cem>quickly due to patients coming\u003C\u002Fem>***” which shows that these devices have been used in humans. Premarket authorization will be required if the intended use of these Implantable Temperature Monitoring Probes is expanded to human use.\u003C\u002Fp>\u003Cp>Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fp>\u003Cp>Specifically, the finished device acceptance activities contained in the respective assembly procedures of your Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) are inadequate because they fail to establish requirements to verify that these devices meet the claimed \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C tolerance specification stated in your marketing brochure. For example, the finished device acceptance activities documented in the “Assembly Instructions ***OT-1” (ECO 10390; Rev. 1; Effective: 4\u002F11\u002F14); “Assembly Instructions***ESO-1” (ECO 10371; Rev. 1; Effective: 6\u002F5\u002F13); “Assembly Instructions***RET-1” (ECO 10371; Rev 1; Effective: 2\u002F18\u002F11); “Assembly Instructions***SST-1” (Effective: 2\u002F18\u002F01); and “Assembly Instructions***SST-2” (Effective: 9\u002F99) lack any tests to ensure these finished devices will remain within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃ for the specified operating range of temperatures, \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃ to \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃, after manufacturing steps such as (but not limited to) welding. Furthermore, you stated that there is no finished device acceptance testing to verify the \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃ tolerance for any of the finished Clinical Temperature Monitoring Probes unless specifically requested by a customer.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You explain that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C tolerance specification is verified during incoming inspection of the thermocouple wires and after completion of the coating step during manufacturing. However, there was no evidence provided that subsequent manufacturing steps such as welding do not adversely change the previously verified tolerances. You further state that you plan to conduct a one-time validation study using a statistically significant sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for each type of Clinical Temperature Monitoring Probe to confirm that your manufacturing process consistently produces probes within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C accuracy tolerance specification. However, no rationale was provided for how the sample size selection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinical probes is statistically significant.\u003C\u002Fp>\u003Cp>Therefore, please provide a response on how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your nonconforming product procedure titled “Part 06: Device Investigation” (Rev 2; Effective: 5\u002F17\u002F10) is inadequate in that it fails to require:\u003C\u002Fp>\u003Cp>A. Identification, documentation, evaluation, segregation, and disposition of nonconformances found during inspections of incoming raw materials, as the current procedure limits identification of nonconformances to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) and Needle Microprobe (MT-D). For example, your Design Engineer stated that they do not document nonconformances found during incoming inspections, including during the incoming inspection of thermocouple wires conducted per the “NIST Compliance Wire Test” procedure (SOP-EG-006; Rev B; Effective: 11\u002F7\u002F24).\u003C\u002Fp>\u003Cp>B. Documentation of the evaluation of a nonconformance to determine the need for an investigation, as the procedure only states “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***.” For example, you were unable to provide a documented evaluation on the need for an investigation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconformances recorded in the “Rejected Logbook” for your Clinical Temperature Monitoring Probes including (but not limited to) the SST-2 on 4\u002F12\u002F24 for “no reading” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); ESO-1 on 6\u002F13\u002F24 for “wire broke Red-blue” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); SST-1 on 8\u002F15\u002F24 for “no reading &amp; duff mark on white area” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); RET-1 on 1\u002F8\u002F25 for “Tip too big” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and OT-1 on 1\u002F21\u002F25 for “scratches” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>). In addition, review of the “Circuit Board Assembly, Fault Record” dated 12\u002F6\u002F23 revealed that at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconformances for “cant [sic] set low batt”, “cant [sic] count up”, or “low battery stays on” found during the pretesting of printed circuit boards (PCBs) pertaining to TH-5 Clinical Electronic Thermometers (Board #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) lacked documentation of the evaluation of a nonconformance to determine the need for an investigation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-004 and CAPA-25-006, your immediate corrections were to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The corrective actions are to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there were no corrective actions to retrospectively document evaluations of nonconformances for your Clinical Electronic Thermometers, Clinical Temperature Monitoring Probes, and Needle Microprobe (MT-D) for a reasonable period of time, to determine whether an investigation is necessary. Despite claims in your response that TH-5 boards in the Pre-Test Log were conforming units, the issues regarding battery and count failures recorded under \"Description of Fault\" column for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBs classify them as nonconformances that require evaluation for the need for an investigation.\u003C\u002Fp>\u003Cp>Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures that define the responsibility for review and the authority for the disposition of nonconforming product. The procedures shall set forth the review and disposition process. Disposition of nonconforming product shall be documented, as required by 21 CFR 820.90(b)(1); and Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications. Rework and reevaluation activities, including a determination of any adverse effect from the network upon the product, shall be documented in the DHR, as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your nonconforming product procedure titled “Part 06: Device Investigation” (Rev 2; Effective: 5\u002F17\u002F10) is inadequate in that it fails to require:\u003C\u002Fp>\u003Cp>A. Documentation of the disposition of the nonconforming product, as required by 21 CFR 820.90(b)(1). For example, you were unable to provide documented dispositions for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconformances recorded in the “Rejected Logbook” for your Clinical Temperature Monitoring Probes including (but not limited to) the SST-1 on 8\u002F15\u002F24 for “no reading &amp; duff mark on white area” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); RET-1 on 1\u002F8\u002F25 for “Tip too big” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and OT-1 on 1\u002F21\u002F25 for “scratches” (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>). In addition, review of the “Circuit Board Assembly, Fault Record” dated 12\u002F6\u002F23 revealed that at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconformances for “cant [sic] set low batt”, “cant [sic] count up”, or “low battery stays on” found during the pretesting of printed circuit boards (PCBs) pertaining to TH-5 Clinical Electronic Thermometers (Board #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) lacked documentation of the dispositions.\u003C\u002Fp>\u003Cp>B. Documentation of the retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). Your procedure lacks such requirements as it only states that “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***” and “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***Initiating department will inspect the rework, complete the log and any other paperwork required before continuing normal assembly process***.” For example, your Production Manager was unable to provide documentation of retesting and reevaluation of reworks, including determination of any adverse effect from the rework, performed on the nonconforming Clinical Temperature Monitoring Probes logged in the “Rejected Logbook” for RET-1 on 4\u002F5\u002F24 (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); SST-2 on 4\u002F12\u002F24 (Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); ESO-1 on 6\u002F13\u002F24 (2 lines, Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and ESO-1 on 6\u002F27\u002F24 (2 lines, Batch # \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-004 and CAPA-25-006, your immediate corrections were to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The corrective actions are to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Despite stating that all future reworks will be \u003Cstrong>(b)(4)\u003C\u002Fstrong>, this corrective action was not included in either of the CAPAs. Therefore, please provide a response on how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your complaint procedures titled “Part 10 Complaint, MDR” (Rev. 5; Effective: 12\u002F24\u002F08), “Processing Complaint Forms” (Rev. 1; Effective: 8\u002F22\u002F06), and “Repair Receiving and Service Report” (Complaint Form 2007; Rev. 2; Effective: 3\u002F25\u002F09) are inadequate in that:\u003C\u002Fp>\u003Cul>\u003Cli>They only require complaint processing of returns from customers and no other forms of written, electronic, or oral communication that allege deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device (i.e., complaint) as defined under 21 CFR 820.3(b). In addition, you stated that medical devices outside of the warranty period are unlikely to be entered into the complaint system. For example, you did not process the complaint received via email on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for incorrect display values of the TH-5 Clinical Electronic Thermometer device as a complaint.\u003C\u002Fli>\u003Cli>They lack instructions on how to evaluate complaints to determine whether they represent an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting (MDR). For example, your Complaint Form 2007 only includes a “Yes” or “No” field under the “Mandatory Report Needed” field.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-002, your immediate correction is to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your corrective actions are to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed up with \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there were no actions identified to retrospectively review all correspondence with customers (e.g., emails, letters, phone calls, etc.) for products outside of the warranty period as well as from non-returns, for a reasonable time frame, to determine whether they should have been processed as complaints. Therefore, please provide a response on how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>6. Failure to investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\u003C\u002Fp>\u003Cp>Specifically, you did not review, evaluate, and investigate complaints which involved the possible failure of a device, labeling, or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example, there was no documented investigation (or reference to another investigation) for the complaint received via email on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>for incorrect display values of the TH-5 Clinical Electronic Thermometer.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-002, your corrective actions are to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed up with \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> (e.g., product, alleged malfunction, impact on user, risk assessment) on the complaint form by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there were no actions identified to investigate any previous correspondence with customers (e.g., emails, letters, phone calls, etc.) that you designate as complaints per a retrospective review when there is an allegation of possible failure of a device, labeling, or packaging to meet any of its specifications. Therefore, please provide a response on how you plan to address this deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that the Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and at least one of your Needle Microprobes (MT-D) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have, for any of these devices, an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>As discussed further below, your firm’s Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and Needle Microprobes (MT-D) are class II devices regulated under 21 CFR 880.2910 (“Clinical electronic thermometer”). These devices are not exempt from premarket notification requirements under § 880.2910 because they have continuous temperature measurement functions. See 21 CFR 888.2910(b)(2); 90 Fed. Reg. 25889, 25890 (June 2025) (“Examples of thermometers with continuous temperature measurement functions include temperature probes intended to monitor body temperature during surgical procedures, temperature probes affixed to the skin of neonates or infants intended to monitor body temperature, thermometer patches affixed to the patient's skin, or thermometers that are swallowed to monitor a patient's body temperature.”).\u003C\u002Fp>\u003Cp>First, the Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP) are signal amplification, conditioning, and display units intended to measure human body temperature when coupled with a transducer and are class II devices regulated under 21 CFR 880.2910.\u003C\u002Fp>\u003Cp>Your marketing materials indicate that these thermometers are intended for recording human temperature measurements. For example, page 3 of your firm’s product brochure states that the Clinical Electronic Thermometer models (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP) are intended for “hospital use” and describe “clinical uses” of the thermometers including “profiling tumor temperature during cancer hyperthermia and measuring myocardial temperature during bypass surgery.” In addition, your firm’s website (https:\u002F\u002Fwww.physitemp.com\u002F) states that all of the thermometer model numbers referenced above are “ideal for laboratory or hospital use” and are “intended for continuous monitoring in the hospital or laboratory.” Because these products are intended to continuously measure human body temperature, they are not exempt from premarket notification requirements (see 21 CFR 880.2910(b)(2)).\u003C\u002Fp>\u003Cp>Second, the Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) are transducers intended to measure human body temperature when coupled with an electronic signal amplification, condition, and display unit, and are class II devices regulated under 21 CFR 880.2910.\u003C\u002Fp>\u003Cp>Your marketing materials indicate that these probes are either compatible with the aforementioned Clinical Electronic Thermometers or with other marketed clinical electronic thermometers. For example, your firm’s website lists probe models OT-1, ESO-1, and RET-1 as “compatible probes” with all of the aforementioned Clinical Electronic Thermometer models and lists probe models SST-1 and SST-2 as “compatible probes” with Clinical Electronic Thermometer model TH-8\u002FAOP.\u003C\u002Fp>\u003Cp>Your marketing materials also indicate that these probes are intended for recording human temperature measurements. For example, page 6 of your firm’s product brochure lists all of the probe model numbers referenced above under the heading “Clinical Probes”; page 6 of your firm’s product brochure states that RET-1 is for human use; and page 4 of your firm’s product brochure contains a photograph showing SST-1 being held against a human forearm. In addition, your firm’s Suggested Sterilizing Cycle Parameters for probe models ESO-1, RET-1, SST-1, and SST-2 states that users should refer to “your hospital standard procedure for a reusable syringe or sterile O.R. pack,” demonstrating that the instructions are for users of the probes in a hospital setting. Also, your firm’s website indicates that probe models OT-1, ESO-1, RET-1, SST-1, and SST-2 are intended for measuring human temperature on the skin and in the mouth, esophagus, and rectum, and their clinical use in hospitals would include temperature measurements on patients. Lastly, your firm’s website provides information for probe models OT-1, ESO-1, RET-1, SST-1, and SST-2 regarding “[w]hen probe is used for continuous measurements.” Because these probes are intended to measure continuous body temperature, they are not exempt from premarket notification requirements (see 21 CFR 880.2910(b)(2)).\u003C\u002Fp>\u003Cp>Third, at least one of your firm’s Needle Microprobes (MT-D) is a transducer intended to measure human body temperature when coupled with an electronic signal amplification, condition, and display unit, and is a class II device regulated under 21 CFR 880.2910.\u003C\u002Fp>\u003Cp>Your marketing materials indicate that these microprobes are compatible with the aforementioned Clinical Electronic Thermometers. For example, page 7 of your firm’s product brochure includes a number of different microprobes, including microprobe model MT-D, compatible with the Thermalert Monitoring Thermometers (i.e., Clinical Electronic Thermometers), and your firm’s website lists MT-D as a “compatible probe []” with thermometer models TH-5, TH-5\u002FAOP, and TH-8.\u003C\u002Fp>\u003Cp>Your marketing materials also indicate that some of these microprobes are intended for recording human temperature measurements. For example, page 7 of your firm’s product brochure describes microprobe model MT-D as for “locating inflammation, arteries, etc. Also for dental use.” In addition, your firm’s website states that microprobe model MT-D is “ideal for dental applications,” and provides information for “when probe is used for continuous measurements.” Because these microprobes are intended to measure continuous body temperature, they are not exempt from premarket notification requirements (see 21 CFR 880.2910(b)(2)).\u003C\u002Fp>\u003Cp>During the inspection, you stated that you believe the subject devices are pre-amendment devices. However, you have not provided evidence beyond your assertions to demonstrate that the subject devices, in their present form, were labeled, promoted, and introduced into interstate commerce as clinical electronic thermometers prior to May 28, 1976. Your firm's failure to submit 510(k)s for these devices has prevented FDA from determining whether these devices are substantially equivalent to an appropriate predicate device and whether there is reasonable assurance of the safety and effectiveness of these devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection (also) revealed that you have failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17 for your firm’s Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and at least one of your Needle Microprobes (MT-D). For example, during the inspection, your firm presented its document titled “Standard Operating Procedure Part 10: Complaint, MDR”, Rev 5, dated 12\u002F24\u002F2008, as its written MDR procedure. Upon review, we determined that this one‐paragraph MDR procedure does not contain sufficient information to demonstrate that it was developed in accordance with the requirements of 21 CFR 803.17.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and conclude that it is not adequate. In the response, your firm provided a copy of its revised MDR procedure titled “Medical Device Reporting (MDR)”, SOP‐QA‐044, Rev. A, dated July 2, 2025. Your firm also indicated plans to conduct staff training on the revised procedure and to perform a retrospective review of all complaints received over the past four years. Please note that both the training and retrospective review are still ongoing, and no evidence has been provided to assess their adequacy. However, upon review of the revised procedure, we noted the following deficiencies:\u003C\u002Fp>\u003Cp>1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, and the description in 21 CFR 803.20(c)(1) of the type of information that “reasonably suggests” a reportable event, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50.\u003C\u002Fp>\u003Cp>2. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports to the FDA, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\u003C\u002Fp>\u003Cp>a. Instructions for how to complete the FDA 3500A form.\u003C\u002Fp>\u003Cp>b. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession.\u003C\u002Fp>\u003Cp>c. The circumstances under which your firm must submit supplement or follow-up reports and the requirements for such reports, as required by 21 CFR 803.56.\u003C\u002Fp>\u003Cp>We note that a device is deemed misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish material or information respecting the device required by or under section 519 of the Act, 21 U.S.C. § 360i, and under 21 CFR Part 803 - Medical Device Reporting.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification (UDI) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, the TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting this device. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Our inspection revealed that your firm designs the finished product label for your TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 devices and final product labeling reflects your firm’s name, address, and website. Physitemp Instruments, LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting this device.\u003C\u002Fp>\u003Cp>Based on review of the Global Unique Device Identification Database (GUDID) on November 3, 2025, there is no company of “Physitemp” found when searching for the names of the various versions\u002Fmodels described in your firm’s marketing materials: TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2. In addition, the following listings and premarket numbers your firm registers and lists were not found in GUDID: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 717394” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:&nbsp;\u003C\u002Fp>\u003Cp>Yirelisa Alcantara, QA Regulatory Coordinator, yalcantara@physitemp.com\u003Cbr>David Pendleton, President and CEO of Glas-Col, LLC, pinnacle@glascol.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMichele J. Cantwell\n\nRecipient Title\n\nVice President of Sales and Marketing\n\nPhysitemp Instruments, LLC\n\n189 Sargeant Avenue\n\nClifton, NJ 07013\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 717394\nNovember 12, 2025\nDear Ms. Cantwell:\nDuring an inspection of your firm located in Clifton, NJ from April 29, 2025 through June 18, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and a Needle Microprobe (MT-D). These products are intended to measure human body temperature in clinical settings, for example, profiling tumor temperature during cancer hyperthermia and measuring myocardial temperature during bypass surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Yirelisa Alcantara, Quality Assurance Regulatory Coordinator, dated (b)(4), concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you failed to define and document procedures for process validation. For example, the following processes were not validated or adequately validated to ensure your Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) and Needle Microprobe (MT-D) meet pre-determined specifications for sterility and laser welding:\nA. (b)(4) Sterilization\nYou have not conducted validations of the (b)(4) sterilization method documented in the respective sterilization guides you supply to customers for sterilization of your esophageal (ESO-1) and rectal (RET-1) Clinical Temperature Monitoring Probes and Needle Microprobe (MT-D) to ensure they consistently produce product that meets pre-determined specifications for sterility.\nMoreover, the (b)(4) Sterility Tests for “Mixed Skin Sensors” and “Skin Sensors” conducted between (b)(4) and (b)(4) are inadequate because you were unable to provide objective evidence that the study included the current versions of your clinical skin sensor Clinical Temperature Monitoring Probes (SST-1 and SST-2) as well as other information such as (but not limited to) load configurations and raw data.\nB. Laser Welding\nYour installation qualifications titled “(b)(4) Installation Qualification” (Rev A; Effective: 4\u002F29\u002F24) and “(b)(4) Operation Qualification” (Rev A; Effective: 4\u002F29\u002F24) are incomplete because they failed to ensure that the (b)(4) (Model #: (b)(4); SN #: (b)(4)), used to weld thermocouple wires of your Clinical Temperature Monitoring Probes and Needle Microprobe (MT-D), was installed in accordance with the manufacturer’s electrical requirements for input power voltage and grounding, as described in the “start preparing” section of the (b)(4) User Manual. Furthermore, you have not conducted a validation of your laser welding process to ensure it consistently produces product that meets pre-determined specifications for welding.\nWe reviewed your firm’s response and conclude that it is not adequate. In response to the (b)(4) sterilization validation, you state that the formal (b)(4) validation for skin sensor probes was provided to the investigator during the inspection. However, these studies were found to be inadequate because you were unable to provide objective evidence that they included the current versions of your Clinical Temperature Monitoring Probes (SST-1 and SST-2) as well as other information such as (but not limited to) load configurations and raw data. Overall, your response failed to include any corrective actions to conduct (b)(4) sterilization validations for your Clinical Temperature Monitoring Probes and Needle Microprobe (MT-D) which are intended for human use.\nIn response to the laser welding validation, you state that there was a mix-up in the documentation that was provided to the investigator and that the current in use laser welder is the (b)(4), not the (b)(4). However, this contradicts the effective dates of (b)(4), for the “(b)(4) Installation Qualification” and “(b)(4) Operation Qualification” which were provided to the investigator during the inspection which point to the (b)(4) Welder as the equipment in current use. Under CAPA-25-003, you removed all legacy material for the (b)(4). Your corrective actions are to (b)(4) by (b)(4), and (b)(4) by (b)(4). By (b)(4), you plan to (b)(4) on (b)(4). In addition, you plan to (b)(4). However, there were no corrective actions identified to define and document an overarching procedure to conduct process validations, with a high degree of assurance, to ensure that your processes consistently produce products that meets pre-determined specifications at worst case and nominal operating parameters.\nIn your response, you also point out that the requirements of 21 CFR 820.75(a) with regards to (b)(4) sterilization validation for the Implantable Temperature Monitoring Probes (IT-14; IT-18 series; IT-21; IT-23; IT-IE) do not apply because these probes are primarily used in general laboratory research applications such as liquid vials, tissue culture, ex-vivo tissue samples, and subcutaneous use in living research animals and not human use. Under CAPA 25-007, you reviewed all labeling (e.g., instructions, promotional materials, etc.) for the Implantable Temperature Monitoring Probes and communicated the intended use to the sales and customer support teams. The corrective actions are to (b)(4) by (b)(4); update the (b)(4) by (b)(4); and (b)(4) on the (b)(4) by (b)(4). However, you have not identified whether any actions should be taken that are commensurate with the risk of customers using the Implantable Temperature Monitoring Probes already in the field on humans due to ambiguous labeling and for which no (b)(4), autoclaving, (b)(4), hermetic sealing, or laser welding validations were conducted. During correspondence with a customer between (b)(4), through (b)(4), you received a complaint (# 9462) for a broken wire and battery box for the IT-18EXLONG (Batch # (b)(4)) Implantable Temperature Monitoring Probe with a request for replacement “***quickly due to patients coming***” which shows that these devices have been used in humans. Premarket authorization will be required if the intended use of these Implantable Temperature Monitoring Probes is expanded to human use.\nPlease provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\nSpecifically, the finished device acceptance activities contained in the respective assembly procedures of your Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) are inadequate because they fail to establish requirements to verify that these devices meet the claimed (b)(4)°C tolerance specification stated in your marketing brochure. For example, the finished device acceptance activities documented in the “Assembly Instructions ***OT-1” (ECO 10390; Rev. 1; Effective: 4\u002F11\u002F14); “Assembly Instructions***ESO-1” (ECO 10371; Rev. 1; Effective: 6\u002F5\u002F13); “Assembly Instructions***RET-1” (ECO 10371; Rev 1; Effective: 2\u002F18\u002F11); “Assembly Instructions***SST-1” (Effective: 2\u002F18\u002F01); and “Assembly Instructions***SST-2” (Effective: 9\u002F99) lack any tests to ensure these finished devices will remain within the (b)(4)℃ for the specified operating range of temperatures, (b)(4)℃ to (b)(4)℃, after manufacturing steps such as (but not limited to) welding. Furthermore, you stated that there is no finished device acceptance testing to verify the (b)(4)℃ tolerance for any of the finished Clinical Temperature Monitoring Probes unless specifically requested by a customer.\nWe reviewed your firm’s response and conclude that it is not adequate. You explain that the (b)(4)°C tolerance specification is verified during incoming inspection of the thermocouple wires and after completion of the coating step during manufacturing. However, there was no evidence provided that subsequent manufacturing steps such as welding do not adversely change the previously verified tolerances. You further state that you plan to conduct a one-time validation study using a statistically significant sample size of (b)(4) for each type of Clinical Temperature Monitoring Probe to confirm that your manufacturing process consistently produces probes within the (b)(4)°C accuracy tolerance specification. However, no rationale was provided for how the sample size selection of (b)(4) clinical probes is statistically significant.\nTherefore, please provide a response on how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, your nonconforming product procedure titled “Part 06: Device Investigation” (Rev 2; Effective: 5\u002F17\u002F10) is inadequate in that it fails to require:\nA. Identification, documentation, evaluation, segregation, and disposition of nonconformances found during inspections of incoming raw materials, as the current procedure limits identification of nonconformances to (b)(4), (b)(4), and (b)(4) of Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) and Needle Microprobe (MT-D). For example, your Design Engineer stated that they do not document nonconformances found during incoming inspections, including during the incoming inspection of thermocouple wires conducted per the “NIST Compliance Wire Test” procedure (SOP-EG-006; Rev B; Effective: 11\u002F7\u002F24).\nB. Documentation of the evaluation of a nonconformance to determine the need for an investigation, as the procedure only states “***(b)(4)***(b)(4)***.” For example, you were unable to provide a documented evaluation on the need for an investigation for (b)(4) nonconformances recorded in the “Rejected Logbook” for your Clinical Temperature Monitoring Probes including (but not limited to) the SST-2 on 4\u002F12\u002F24 for “no reading” (Batch # (b)(4)); ESO-1 on 6\u002F13\u002F24 for “wire broke Red-blue” (Batch # (b)(4)); SST-1 on 8\u002F15\u002F24 for “no reading & duff mark on white area” (Batch # (b)(4)); RET-1 on 1\u002F8\u002F25 for “Tip too big” (Batch # (b)(4)); and OT-1 on 1\u002F21\u002F25 for “scratches” (Batch # (b)(4)). In addition, review of the “Circuit Board Assembly, Fault Record” dated 12\u002F6\u002F23 revealed that at least (b)(4) nonconformances for “cant [sic] set low batt”, “cant [sic] count up”, or “low battery stays on” found during the pretesting of printed circuit boards (PCBs) pertaining to TH-5 Clinical Electronic Thermometers (Board #: (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4) and (b)(4)) lacked documentation of the evaluation of a nonconformance to determine the need for an investigation.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-004 and CAPA-25-006, your immediate corrections were to (b)(4). The corrective actions are to (b)(4) by (b)(4); (b)(4); (b)(4) by (b)(4). However, there were no corrective actions to retrospectively document evaluations of nonconformances for your Clinical Electronic Thermometers, Clinical Temperature Monitoring Probes, and Needle Microprobe (MT-D) for a reasonable period of time, to determine whether an investigation is necessary. Despite claims in your response that TH-5 boards in the Pre-Test Log were conforming units, the issues regarding battery and count failures recorded under \"Description of Fault\" column for all (b)(4) PCBs classify them as nonconformances that require evaluation for the need for an investigation.\nPlease provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures that define the responsibility for review and the authority for the disposition of nonconforming product. The procedures shall set forth the review and disposition process. Disposition of nonconforming product shall be documented, as required by 21 CFR 820.90(b)(1); and Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications. Rework and reevaluation activities, including a determination of any adverse effect from the network upon the product, shall be documented in the DHR, as required by 21 CFR 820.90(b)(2).\nSpecifically, your nonconforming product procedure titled “Part 06: Device Investigation” (Rev 2; Effective: 5\u002F17\u002F10) is inadequate in that it fails to require:\nA. Documentation of the disposition of the nonconforming product, as required by 21 CFR 820.90(b)(1). For example, you were unable to provide documented dispositions for (b)(4) of the (b)(4) nonconformances recorded in the “Rejected Logbook” for your Clinical Temperature Monitoring Probes including (but not limited to) the SST-1 on 8\u002F15\u002F24 for “no reading & duff mark on white area” (Batch # (b)(4)); RET-1 on 1\u002F8\u002F25 for “Tip too big” (Batch # (b)(4)); and OT-1 on 1\u002F21\u002F25 for “scratches” (Batch # (b)(4)). In addition, review of the “Circuit Board Assembly, Fault Record” dated 12\u002F6\u002F23 revealed that at least (b)(4) nonconformances for “cant [sic] set low batt”, “cant [sic] count up”, or “low battery stays on” found during the pretesting of printed circuit boards (PCBs) pertaining to TH-5 Clinical Electronic Thermometers (Board #: (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4) and (b)(4)) lacked documentation of the dispositions.\nB. Documentation of the retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). Your procedure lacks such requirements as it only states that “***(b)(4)***” and “***(b)(4)***Initiating department will inspect the rework, complete the log and any other paperwork required before continuing normal assembly process***.” For example, your Production Manager was unable to provide documentation of retesting and reevaluation of reworks, including determination of any adverse effect from the rework, performed on the nonconforming Clinical Temperature Monitoring Probes logged in the “Rejected Logbook” for RET-1 on 4\u002F5\u002F24 (Batch # (b)(4)); SST-2 on 4\u002F12\u002F24 (Batch # (b)(4)); ESO-1 on 6\u002F13\u002F24 (2 lines, Batch # (b)(4)); and ESO-1 on 6\u002F27\u002F24 (2 lines, Batch # (b)(4)).\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-004 and CAPA-25-006, your immediate corrections were to (b)(4). The corrective actions are to (b)(4) by (b)(4); (b)(4) by (b)(4). Despite stating that all future reworks will be (b)(4), this corrective action was not included in either of the CAPAs. Therefore, please provide a response on how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n5. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your complaint procedures titled “Part 10 Complaint, MDR” (Rev. 5; Effective: 12\u002F24\u002F08), “Processing Complaint Forms” (Rev. 1; Effective: 8\u002F22\u002F06), and “Repair Receiving and Service Report” (Complaint Form 2007; Rev. 2; Effective: 3\u002F25\u002F09) are inadequate in that:\nThey only require complaint processing of returns from customers and no other forms of written, electronic, or oral communication that allege deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device (i.e., complaint) as defined under 21 CFR 820.3(b). In addition, you stated that medical devices outside of the warranty period are unlikely to be entered into the complaint system. For example, you did not process the complaint received via email on (b)(4), for incorrect display values of the TH-5 Clinical Electronic Thermometer device as a complaint.\nThey lack instructions on how to evaluate complaints to determine whether they represent an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting (MDR). For example, your Complaint Form 2007 only includes a “Yes” or “No” field under the “Mandatory Report Needed” field.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-002, your immediate correction is to (b)(4) by (b)(4). Your corrective actions are to (b)(4) by (b)(4) followed up with (b)(4) by (b)(4); (b)(4) by (b)(4); (b)(4) by (b)(4); and (b)(4) by (b)(4). However, there were no actions identified to retrospectively review all correspondence with customers (e.g., emails, letters, phone calls, etc.) for products outside of the warranty period as well as from non-returns, for a reasonable time frame, to determine whether they should have been processed as complaints. Therefore, please provide a response on how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n6. Failure to investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\nSpecifically, you did not review, evaluate, and investigate complaints which involved the possible failure of a device, labeling, or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example, there was no documented investigation (or reference to another investigation) for the complaint received via email on (b)(4), (b)(4) for incorrect display values of the TH-5 Clinical Electronic Thermometer.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA-25-002, your corrective actions are to (b)(4) by (b)(4) followed up with (b)(4) by (b)(4); (b)(4) (e.g., product, alleged malfunction, impact on user, risk assessment) on the complaint form by (b)(4); and (b)(4) by (b)(4). However, there were no actions identified to investigate any previous correspondence with customers (e.g., emails, letters, phone calls, etc.) that you designate as complaints per a retrospective review when there is an allegation of possible failure of a device, labeling, or packaging to meet any of its specifications. Therefore, please provide a response on how you plan to address this deficiency.\nUnapproved Device Violation(s)\nOur inspection also revealed that the Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and at least one of your Needle Microprobes (MT-D) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have, for any of these devices, an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nAs discussed further below, your firm’s Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and Needle Microprobes (MT-D) are class II devices regulated under 21 CFR 880.2910 (“Clinical electronic thermometer”). These devices are not exempt from premarket notification requirements under § 880.2910 because they have continuous temperature measurement functions. See 21 CFR 888.2910(b)(2); 90 Fed. Reg. 25889, 25890 (June 2025) (“Examples of thermometers with continuous temperature measurement functions include temperature probes intended to monitor body temperature during surgical procedures, temperature probes affixed to the skin of neonates or infants intended to monitor body temperature, thermometer patches affixed to the patient's skin, or thermometers that are swallowed to monitor a patient's body temperature.”).\nFirst, the Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP) are signal amplification, conditioning, and display units intended to measure human body temperature when coupled with a transducer and are class II devices regulated under 21 CFR 880.2910.\nYour marketing materials indicate that these thermometers are intended for recording human temperature measurements. For example, page 3 of your firm’s product brochure states that the Clinical Electronic Thermometer models (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP) are intended for “hospital use” and describe “clinical uses” of the thermometers including “profiling tumor temperature during cancer hyperthermia and measuring myocardial temperature during bypass surgery.” In addition, your firm’s website (https:\u002F\u002Fwww.physitemp.com\u002F) states that all of the thermometer model numbers referenced above are “ideal for laboratory or hospital use” and are “intended for continuous monitoring in the hospital or laboratory.” Because these products are intended to continuously measure human body temperature, they are not exempt from premarket notification requirements (see 21 CFR 880.2910(b)(2)).\nSecond, the Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2) are transducers intended to measure human body temperature when coupled with an electronic signal amplification, condition, and display unit, and are class II devices regulated under 21 CFR 880.2910.\nYour marketing materials indicate that these probes are either compatible with the aforementioned Clinical Electronic Thermometers or with other marketed clinical electronic thermometers. For example, your firm’s website lists probe models OT-1, ESO-1, and RET-1 as “compatible probes” with all of the aforementioned Clinical Electronic Thermometer models and lists probe models SST-1 and SST-2 as “compatible probes” with Clinical Electronic Thermometer model TH-8\u002FAOP.\nYour marketing materials also indicate that these probes are intended for recording human temperature measurements. For example, page 6 of your firm’s product brochure lists all of the probe model numbers referenced above under the heading “Clinical Probes”; page 6 of your firm’s product brochure states that RET-1 is for human use; and page 4 of your firm’s product brochure contains a photograph showing SST-1 being held against a human forearm. In addition, your firm’s Suggested Sterilizing Cycle Parameters for probe models ESO-1, RET-1, SST-1, and SST-2 states that users should refer to “your hospital standard procedure for a reusable syringe or sterile O.R. pack,” demonstrating that the instructions are for users of the probes in a hospital setting. Also, your firm’s website indicates that probe models OT-1, ESO-1, RET-1, SST-1, and SST-2 are intended for measuring human temperature on the skin and in the mouth, esophagus, and rectum, and their clinical use in hospitals would include temperature measurements on patients. Lastly, your firm’s website provides information for probe models OT-1, ESO-1, RET-1, SST-1, and SST-2 regarding “[w]hen probe is used for continuous measurements.” Because these probes are intended to measure continuous body temperature, they are not exempt from premarket notification requirements (see 21 CFR 880.2910(b)(2)).\nThird, at least one of your firm’s Needle Microprobes (MT-D) is a transducer intended to measure human body temperature when coupled with an electronic signal amplification, condition, and display unit, and is a class II device regulated under 21 CFR 880.2910.\nYour marketing materials indicate that these microprobes are compatible with the aforementioned Clinical Electronic Thermometers. For example, page 7 of your firm’s product brochure includes a number of different microprobes, including microprobe model MT-D, compatible with the Thermalert Monitoring Thermometers (i.e., Clinical Electronic Thermometers), and your firm’s website lists MT-D as a “compatible probe []” with thermometer models TH-5, TH-5\u002FAOP, and TH-8.\nYour marketing materials also indicate that some of these microprobes are intended for recording human temperature measurements. For example, page 7 of your firm’s product brochure describes microprobe model MT-D as for “locating inflammation, arteries, etc. Also for dental use.” In addition, your firm’s website states that microprobe model MT-D is “ideal for dental applications,” and provides information for “when probe is used for continuous measurements.” Because these microprobes are intended to measure continuous body temperature, they are not exempt from premarket notification requirements (see 21 CFR 880.2910(b)(2)).\nDuring the inspection, you stated that you believe the subject devices are pre-amendment devices. However, you have not provided evidence beyond your assertions to demonstrate that the subject devices, in their present form, were labeled, promoted, and introduced into interstate commerce as clinical electronic thermometers prior to May 28, 1976. Your firm's failure to submit 510(k)s for these devices has prevented FDA from determining whether these devices are substantially equivalent to an appropriate predicate device and whether there is reasonable assurance of the safety and effectiveness of these devices.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection (also) revealed that you have failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17 for your firm’s Clinical Electronic Thermometers (TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP), Clinical Temperature Monitoring Probes (OT-1; ESO-1; RET-1; SST-1; SST-2), and at least one of your Needle Microprobes (MT-D). For example, during the inspection, your firm presented its document titled “Standard Operating Procedure Part 10: Complaint, MDR”, Rev 5, dated 12\u002F24\u002F2008, as its written MDR procedure. Upon review, we determined that this one‐paragraph MDR procedure does not contain sufficient information to demonstrate that it was developed in accordance with the requirements of 21 CFR 803.17.\nWe reviewed your firm’s response dated (b)(4), and conclude that it is not adequate. In the response, your firm provided a copy of its revised MDR procedure titled “Medical Device Reporting (MDR)”, SOP‐QA‐044, Rev. A, dated July 2, 2025. Your firm also indicated plans to conduct staff training on the revised procedure and to perform a retrospective review of all complaints received over the past four years. Please note that both the training and retrospective review are still ongoing, and no evidence has been provided to assess their adequacy. However, upon review of the revised procedure, we noted the following deficiencies:\n1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, and the description in 21 CFR 803.20(c)(1) of the type of information that “reasonably suggests” a reportable event, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50.\n2. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports to the FDA, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\na. Instructions for how to complete the FDA 3500A form.\nb. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession.\nc. The circumstances under which your firm must submit supplement or follow-up reports and the requirements for such reports, as required by 21 CFR 803.56.\nWe note that a device is deemed misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish material or information respecting the device required by or under section 519 of the Act, 21 U.S.C. § 360i, and under 21 CFR Part 803 - Medical Device Reporting.\nUnique Device Identification (UDI) Violation(s)\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 do not bear such a UDI.\nSpecifically, the labels for TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\nIn addition, the TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting this device. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Our inspection revealed that your firm designs the finished product label for your TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2 devices and final product labeling reflects your firm’s name, address, and website. Physitemp Instruments, LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting this device.\nBased on review of the Global Unique Device Identification Database (GUDID) on November 3, 2025, there is no company of “Physitemp” found when searching for the names of the various versions\u002Fmodels described in your firm’s marketing materials: TH-5; TH-5\u002FAOP; TH-8; TH-8\u002FAOP, OT-1; ESO-1; RET-1; MT-D; SST-1; and SST-2. In addition, the following listings and premarket numbers your firm registers and lists were not found in GUDID: (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 717394” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nYirelisa Alcantara, QA Regulatory Coordinator, yalcantara@physitemp.com\nDavid Pendleton, President and CEO of Glas-Col, LLC, pinnacle@glascol.com","Physitemp Instruments, LLC","physitemp-instruments-llc-717394-11122025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphysitemp-instruments-llc-717394-11122025","2026-10-26T08:09:41.86116+00:00","2026-03-31","717394","Michele J. Cantwell","2026-08-19T04:49:55.744+00:00","2025-11-12",13,{"510k":266,"classification":267,"enforcement":268,"event":269,"event_backfill":270,"pma":271,"warning_letter":272},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]